PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26690098-0	2015	1-Deoxynojirimycin Alleviates Insulin Resistance via Activation of Insulin Signaling PI3K/AKT Pathway in Skeletal Muscle of db/db Mice.	1-Deoxynojirimycin	0-18	thymoma viral proto-oncogene 1	Mus musculus	90-93
26690098-1	2015	1-Deoxynojirimycin (DNJ) is widely used for the treatment of diabetes mellitus as an inhibitor of intestinal alpha-glucosidase.	1-Deoxynojirimycin	0-18	sucrase isomaltase (alpha-glucosidase)	Mus musculus	109-126
26690098-1	2015	1-Deoxynojirimycin (DNJ) is widely used for the treatment of diabetes mellitus as an inhibitor of intestinal alpha-glucosidase.	1-Deoxynojirimycin	20-23	sucrase isomaltase (alpha-glucosidase)	Mus musculus	109-126
26690098-10	2015	These results indicate that DNJ significantly improved insulin sensitivity via activating insulin signaling PI3K/AKT pathway in skeletal muscle of db/db mice.	1-Deoxynojirimycin	28-31	thymoma viral proto-oncogene 1	Mus musculus	113-116
26356422-0	2015	Synthetic deoxynojirimycin derivatives bearing a thiolated, fluorinated or unsaturated N-alkyl chain: identification of potent alpha-glucosidase and trehalase inhibitors as well as F508del-CFTR correctors.	1-Deoxynojirimycin	10-26	sucrase-isomaltase	Homo sapiens	127-144
26356422-0	2015	Synthetic deoxynojirimycin derivatives bearing a thiolated, fluorinated or unsaturated N-alkyl chain: identification of potent alpha-glucosidase and trehalase inhibitors as well as F508del-CFTR correctors.	1-Deoxynojirimycin	10-26	trehalase	Homo sapiens	149-158
26356422-0	2015	Synthetic deoxynojirimycin derivatives bearing a thiolated, fluorinated or unsaturated N-alkyl chain: identification of potent alpha-glucosidase and trehalase inhibitors as well as F508del-CFTR correctors.	1-Deoxynojirimycin	10-26	CF transmembrane conductance regulator	Homo sapiens	189-193
26075699-0	2015	Mulberry 1-Deoxynojirimycin Inhibits Adipogenesis by Repression of the ERK/PPARgamma Signaling Pathway in Porcine Intramuscular Adipocytes.	1-Deoxynojirimycin	9-27	mitogen-activated protein kinase 1	Homo sapiens	71-74
26075699-0	2015	Mulberry 1-Deoxynojirimycin Inhibits Adipogenesis by Repression of the ERK/PPARgamma Signaling Pathway in Porcine Intramuscular Adipocytes.	1-Deoxynojirimycin	9-27	peroxisome proliferator activated receptor gamma	Homo sapiens	75-84
26075699-3	2015	Here, we found that both DNJ (2.0, 3.0, 4.0, 5.0, and 6.0 muM) and rosiglitazone (RSG; 0.1, 0.2, 0.3, 0.4, and 0.5 mM) had no effect on cell viability.	1-Deoxynojirimycin	25-28	latexin	Homo sapiens	58-61
26075699-4	2015	Moreover, 4 muM DNJ significantly inhibited adipogenesis, whereas 0.4 mM RSG increased lipogenesis of porcine intramuscular adipocytes.	1-Deoxynojirimycin	16-19	latexin	Homo sapiens	12-15
26075699-5	2015	Interestingly, DNJ sharply inhibited phosphorylation of extracellular regulated protein kinases 1/2 (ERK1/2), but did not change phosphorylation of AKT (protein kinase B) in intramuscular adipocytes.	1-Deoxynojirimycin	15-18	mitogen-activated protein kinase 3	Homo sapiens	56-99
26075699-5	2015	Interestingly, DNJ sharply inhibited phosphorylation of extracellular regulated protein kinases 1/2 (ERK1/2), but did not change phosphorylation of AKT (protein kinase B) in intramuscular adipocytes.	1-Deoxynojirimycin	15-18	mitogen-activated protein kinase 3	Homo sapiens	101-107
26075699-7	2015	On the basis of the above findings, we suggest that DNJ inhibited adipogenesis through the ERK/PPARgamma signaling pathway in porcine intramuscular adipocytes.	1-Deoxynojirimycin	52-55	mitogen-activated protein kinase 1	Homo sapiens	91-94
26075699-7	2015	On the basis of the above findings, we suggest that DNJ inhibited adipogenesis through the ERK/PPARgamma signaling pathway in porcine intramuscular adipocytes.	1-Deoxynojirimycin	52-55	peroxisome proliferator activated receptor gamma	Homo sapiens	95-104
25915583-4	2015	Glucosylceramide synthase (GCS) inhibitors, including the clinically approved agent N-butyl-deoxynojirimycin (NB-DNJ), prevented OC development and activation by disrupting RANKL-induced localization of TRAF6 and c-SRC into lipid rafts and preventing nuclear accumulation of transcriptional activator NFATc1.	1-Deoxynojirimycin	113-116	UDP-glucose ceramide glucosyltransferase	Mus musculus	0-25
25915583-4	2015	Glucosylceramide synthase (GCS) inhibitors, including the clinically approved agent N-butyl-deoxynojirimycin (NB-DNJ), prevented OC development and activation by disrupting RANKL-induced localization of TRAF6 and c-SRC into lipid rafts and preventing nuclear accumulation of transcriptional activator NFATc1.	1-Deoxynojirimycin	113-116	UDP-glucose ceramide glucosyltransferase	Mus musculus	27-30
25915583-4	2015	Glucosylceramide synthase (GCS) inhibitors, including the clinically approved agent N-butyl-deoxynojirimycin (NB-DNJ), prevented OC development and activation by disrupting RANKL-induced localization of TRAF6 and c-SRC into lipid rafts and preventing nuclear accumulation of transcriptional activator NFATc1.	1-Deoxynojirimycin	113-116	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	173-178
25915583-4	2015	Glucosylceramide synthase (GCS) inhibitors, including the clinically approved agent N-butyl-deoxynojirimycin (NB-DNJ), prevented OC development and activation by disrupting RANKL-induced localization of TRAF6 and c-SRC into lipid rafts and preventing nuclear accumulation of transcriptional activator NFATc1.	1-Deoxynojirimycin	113-116	TNF receptor-associated factor 6	Mus musculus	203-208
25915583-4	2015	Glucosylceramide synthase (GCS) inhibitors, including the clinically approved agent N-butyl-deoxynojirimycin (NB-DNJ), prevented OC development and activation by disrupting RANKL-induced localization of TRAF6 and c-SRC into lipid rafts and preventing nuclear accumulation of transcriptional activator NFATc1.	1-Deoxynojirimycin	113-116	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	301-307
25250725-1	2014	This work details the evaluation of a number of N-alkylated deoxynojirimycin derivatives on their merits as dual glucosylceramide synthase/neutral glucosylceramidase inhibitors.	1-Deoxynojirimycin	60-76	UDP-glucose ceramide glucosyltransferase	Homo sapiens	113-138
25250725-1	2014	This work details the evaluation of a number of N-alkylated deoxynojirimycin derivatives on their merits as dual glucosylceramide synthase/neutral glucosylceramidase inhibitors.	1-Deoxynojirimycin	60-76	glucosylceramidase beta	Homo sapiens	147-165
25036864-3	2014	We have shown previously that the small molecule pharmacological chaperone AT2220 (1-deoxynojirimycin hydrochloride, duvoglustat hydrochloride) binds and stabilizes wild-type as well as multiple mutant forms of GAA, and can lead to higher cellular levels of GAA.	1-Deoxynojirimycin	83-115	glucosidase, alpha, acid	Mus musculus	211-214
25036864-3	2014	We have shown previously that the small molecule pharmacological chaperone AT2220 (1-deoxynojirimycin hydrochloride, duvoglustat hydrochloride) binds and stabilizes wild-type as well as multiple mutant forms of GAA, and can lead to higher cellular levels of GAA.	1-Deoxynojirimycin	83-115	glucosidase, alpha, acid	Mus musculus	258-261
25036864-3	2014	We have shown previously that the small molecule pharmacological chaperone AT2220 (1-deoxynojirimycin hydrochloride, duvoglustat hydrochloride) binds and stabilizes wild-type as well as multiple mutant forms of GAA, and can lead to higher cellular levels of GAA.	1-Deoxynojirimycin	117-142	glucosidase, alpha, acid	Mus musculus	211-214
25036864-3	2014	We have shown previously that the small molecule pharmacological chaperone AT2220 (1-deoxynojirimycin hydrochloride, duvoglustat hydrochloride) binds and stabilizes wild-type as well as multiple mutant forms of GAA, and can lead to higher cellular levels of GAA.	1-Deoxynojirimycin	117-142	glucosidase, alpha, acid	Mus musculus	258-261
24696475-4	2014	The DMJ compounds (+)-DMJ-I-228 and (+)-DMJ-II-121 bind gp120 within the conserved Phe 43 cavity near the CD4-binding site, block CD4 binding, and inhibit HIV-1 infection.	1-Deoxynojirimycin	4-7	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	56-61
24696475-5	2014	Here we show that the DMJ compounds sensitize primary HIV-1, including transmitted/founder viruses, to neutralization by monoclonal antibodies directed against CD4-induced (CD4i) epitopes and the V3 region, two gp120 elements involved in coreceptor binding.	1-Deoxynojirimycin	22-25	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	211-216
24696475-6	2014	Importantly, the DMJ compounds rendered primary HIV-1 sensitive to neutralization by antisera elicited by immunization of rabbits with HIV-1 gp120 cores engineered to assume the CD4-bound state.	1-Deoxynojirimycin	17-20	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	141-146
24244851-8	2013	DDR1 over-expression was associated with increased glycosylation of the beta1 integrin subunit, which when blocked by deoxymannojirimycin, reduced collagen binding.	1-Deoxynojirimycin	118-137	discoidin domain receptor tyrosine kinase 1	Homo sapiens	0-4
24244851-8	2013	DDR1 over-expression was associated with increased glycosylation of the beta1 integrin subunit, which when blocked by deoxymannojirimycin, reduced collagen binding.	1-Deoxynojirimycin	118-137	integrin subunit beta 1	Homo sapiens	72-86
23582447-5	2013	Increasing alkyl linker length between DNJ and triazole groups increases alpha-glucosidase inhibition and reduces the production of viral progeny RNA and the maturation of the envelope polypeptide.	1-Deoxynojirimycin	39-42	sucrase-isomaltase	Homo sapiens	73-90
22766068-8	2012	Activation of hSGLT3 with DNJ (50muM) increased sodium uptake in HK-2 cells by 5.5 fold and this effect could be completely blocked with SGLT inhibitor phlorizin (50muM).	1-Deoxynojirimycin	26-29	solute carrier family 5 member 4	Homo sapiens	14-20
22766068-8	2012	Activation of hSGLT3 with DNJ (50muM) increased sodium uptake in HK-2 cells by 5.5 fold and this effect could be completely blocked with SGLT inhibitor phlorizin (50muM).	1-Deoxynojirimycin	26-29	latexin	Homo sapiens	33-36
22841093-3	2012	As a result, deoxynojirimycin, as a potential alpha-glucosidase inhibitor, was found.	1-Deoxynojirimycin	13-29	sucrase-isomaltase	Homo sapiens	46-63
21982629-8	2011	Treatment with N-butyl-deoxynojirimycin (NB-DNJ), which acts as a pharmacological chaperone for certain mutant forms of GAA, led to attenuation of not only ER stress, but also autophagy in patient fibroblasts.	1-Deoxynojirimycin	44-47	alpha glucosidase	Homo sapiens	120-123
21512716-3	2011	We have demonstrated that it is possible to selectively either strongly inhibit ER-alpha-glucosidases and ceramide glucosyltransferase or restore the activity of CFTR in CF-KM4 cells by varying the length of the alkyl chain linking DNJ and adamantane.	1-Deoxynojirimycin	232-235	CF transmembrane conductance regulator	Homo sapiens	162-166
21454560-8	2011	Inhibitors of N-linked glycosylation (tunicamycin, deoxymannojirimycin, and deoxynojirimycin) also markedly attenuated the inhibitory effect of IGF-I on beta-glycerophosphate-induced mineralization (p < 0.05) and activation of Akt and MAPK.	1-Deoxynojirimycin	51-70	insulin like growth factor 1	Homo sapiens	144-149
21454560-8	2011	Inhibitors of N-linked glycosylation (tunicamycin, deoxymannojirimycin, and deoxynojirimycin) also markedly attenuated the inhibitory effect of IGF-I on beta-glycerophosphate-induced mineralization (p < 0.05) and activation of Akt and MAPK.	1-Deoxynojirimycin	76-92	insulin like growth factor 1	Homo sapiens	144-149
21454560-8	2011	Inhibitors of N-linked glycosylation (tunicamycin, deoxymannojirimycin, and deoxynojirimycin) also markedly attenuated the inhibitory effect of IGF-I on beta-glycerophosphate-induced mineralization (p < 0.05) and activation of Akt and MAPK.	1-Deoxynojirimycin	76-92	AKT serine/threonine kinase 1	Homo sapiens	230-233
21333726-0	2011	Hybrid of 1-deoxynojirimycin and polysaccharide from mulberry leaves treat diabetes mellitus by activating PDX-1/insulin-1 signaling pathway and regulating the expression of glucokinase, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase in alloxan-induced diabetic mice.	1-Deoxynojirimycin	10-28	pancreatic and duodenal homeobox 1	Mus musculus	107-112
21333726-0	2011	Hybrid of 1-deoxynojirimycin and polysaccharide from mulberry leaves treat diabetes mellitus by activating PDX-1/insulin-1 signaling pathway and regulating the expression of glucokinase, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase in alloxan-induced diabetic mice.	1-Deoxynojirimycin	10-28	insulin I	Mus musculus	113-122
21333726-0	2011	Hybrid of 1-deoxynojirimycin and polysaccharide from mulberry leaves treat diabetes mellitus by activating PDX-1/insulin-1 signaling pathway and regulating the expression of glucokinase, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase in alloxan-induced diabetic mice.	1-Deoxynojirimycin	10-28	glucokinase	Mus musculus	174-185
21333726-0	2011	Hybrid of 1-deoxynojirimycin and polysaccharide from mulberry leaves treat diabetes mellitus by activating PDX-1/insulin-1 signaling pathway and regulating the expression of glucokinase, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase in alloxan-induced diabetic mice.	1-Deoxynojirimycin	10-28	glucose-6-phosphatase, catalytic	Mus musculus	225-246
24900342-0	2011	Assessment of partially deoxygenated deoxynojirimycin derivatives as glucosylceramide synthase inhibitors.	1-Deoxynojirimycin	37-53	UDP-glucose ceramide glucosyltransferase	Homo sapiens	69-94
24900342-3	2011	In this work we demonstrate that, in contrast to what is proposed in this model, the C2-hydroxyl of the deoxynojirimycin core is important for GCS inhibition.	1-Deoxynojirimycin	104-120	UDP-glucose ceramide glucosyltransferase	Homo sapiens	143-146
20542873-9	2010	Here, we propose that deoxynojirimycin inhibits the activity of trehalase from C. riparius according to a ligand exclusion model.	1-Deoxynojirimycin	22-38	trehalase	Homo sapiens	64-73
23654233-0	2010	1-Deoxynojirimycin inhibits metastasis of B16F10 melanoma cells by attenuating the activity and expression of matrix metalloproteinases-2 and -9 and altering cell surface glycosylation.	1-Deoxynojirimycin	0-18	matrix metallopeptidase 2	Mus musculus	110-144
23654233-3	2010	1-DNJ significantly inhibited invasion, migration, and cell-matrix adhesion and markedly decreased MMP-2 and MMP-9 activity and mRNA expression.	1-Deoxynojirimycin	0-5	matrix metallopeptidase 2	Mus musculus	99-104
23654233-3	2010	1-DNJ significantly inhibited invasion, migration, and cell-matrix adhesion and markedly decreased MMP-2 and MMP-9 activity and mRNA expression.	1-Deoxynojirimycin	0-5	matrix metallopeptidase 9	Mus musculus	109-114
23654233-4	2010	In contrast, 1-DNJ effectively enhanced the expression of TIMP-2 mRNA.	1-Deoxynojirimycin	13-18	tissue inhibitor of metalloproteinase 2	Mus musculus	58-64
23654233-6	2010	Thus, the antimetastatic effects of 1-DNJ against B16F10 melanoma cells are likely associated with its attenuated activities and expression of MMP-2/9, enhancement of the TIMP-2 mRNA expression, and alterations of the cell surface-binding motif.	1-Deoxynojirimycin	36-41	matrix metallopeptidase 2	Mus musculus	143-150
23654233-6	2010	Thus, the antimetastatic effects of 1-DNJ against B16F10 melanoma cells are likely associated with its attenuated activities and expression of MMP-2/9, enhancement of the TIMP-2 mRNA expression, and alterations of the cell surface-binding motif.	1-Deoxynojirimycin	36-41	tissue inhibitor of metalloproteinase 2	Mus musculus	171-177
20580553-0	2010	Deoxynojirimycin and its hexosaminyl derivatives bind to natural killer cell receptors rNKR-P1A and hCD69.	1-Deoxynojirimycin	0-16	killer cell lectin-like receptor subfamily B, member 1A	Rattus norvegicus	87-95
20580553-0	2010	Deoxynojirimycin and its hexosaminyl derivatives bind to natural killer cell receptors rNKR-P1A and hCD69.	1-Deoxynojirimycin	0-16	CD69 molecule	Homo sapiens	100-105
20565474-2	2010	A hybrid of 1-deoxynojirimycin (DNJ) and an aryl-1,2,3-triazole, which inhibits both an alpha-glucosidase and methionine aminopeptidase-2 (MetAP2), displayed properties associated with inhibition of angiogenesis (Bioorg.	1-Deoxynojirimycin	12-30	maltase-glucoamylase	Bos taurus	88-105
20565474-2	2010	A hybrid of 1-deoxynojirimycin (DNJ) and an aryl-1,2,3-triazole, which inhibits both an alpha-glucosidase and methionine aminopeptidase-2 (MetAP2), displayed properties associated with inhibition of angiogenesis (Bioorg.	1-Deoxynojirimycin	12-30	methionyl aminopeptidase 2	Bos taurus	110-137
20565474-2	2010	A hybrid of 1-deoxynojirimycin (DNJ) and an aryl-1,2,3-triazole, which inhibits both an alpha-glucosidase and methionine aminopeptidase-2 (MetAP2), displayed properties associated with inhibition of angiogenesis (Bioorg.	1-Deoxynojirimycin	12-30	methionyl aminopeptidase 2	Bos taurus	139-145
20565474-2	2010	A hybrid of 1-deoxynojirimycin (DNJ) and an aryl-1,2,3-triazole, which inhibits both an alpha-glucosidase and methionine aminopeptidase-2 (MetAP2), displayed properties associated with inhibition of angiogenesis (Bioorg.	1-Deoxynojirimycin	32-35	maltase-glucoamylase	Bos taurus	88-105
20565474-2	2010	A hybrid of 1-deoxynojirimycin (DNJ) and an aryl-1,2,3-triazole, which inhibits both an alpha-glucosidase and methionine aminopeptidase-2 (MetAP2), displayed properties associated with inhibition of angiogenesis (Bioorg.	1-Deoxynojirimycin	32-35	methionyl aminopeptidase 2	Bos taurus	110-137
20565474-2	2010	A hybrid of 1-deoxynojirimycin (DNJ) and an aryl-1,2,3-triazole, which inhibits both an alpha-glucosidase and methionine aminopeptidase-2 (MetAP2), displayed properties associated with inhibition of angiogenesis (Bioorg.	1-Deoxynojirimycin	32-35	methionyl aminopeptidase 2	Bos taurus	139-145
19914915-4	2010	The PE-labeled OS-9(MRH)-SA bound to HeLaS3 cells in a metal ion-independent manner through amino acid residues homologous to those participating in sugar binding of the cation-dependent mannose 6-phosphate receptor, and this binding was greatly increased by swainsonine, deoxymannojirimycin, or kifunensine treatment.	1-Deoxynojirimycin	272-291	OS9 endoplasmic reticulum lectin	Homo sapiens	15-19
19914915-4	2010	The PE-labeled OS-9(MRH)-SA bound to HeLaS3 cells in a metal ion-independent manner through amino acid residues homologous to those participating in sugar binding of the cation-dependent mannose 6-phosphate receptor, and this binding was greatly increased by swainsonine, deoxymannojirimycin, or kifunensine treatment.	1-Deoxynojirimycin	272-291	OS9 endoplasmic reticulum lectin	Homo sapiens	20-23
19914915-4	2010	The PE-labeled OS-9(MRH)-SA bound to HeLaS3 cells in a metal ion-independent manner through amino acid residues homologous to those participating in sugar binding of the cation-dependent mannose 6-phosphate receptor, and this binding was greatly increased by swainsonine, deoxymannojirimycin, or kifunensine treatment.	1-Deoxynojirimycin	272-291	mannose-6-phosphate receptor, cation dependent	Homo sapiens	170-215
19904984-2	2009	Photoexcitation of DMJ-An produces DMJ(+*)-An(-*) quantitatively, so that An(-*) acts as a high potential electron donor, which rapidly transfers an electron to NI yielding a long-lived spin-coherent radical ion pair (DMJ(+*)-An-Ph(n)-NI(-*)).	1-Deoxynojirimycin	19-22	spindlin 1	Homo sapiens	186-190
19904984-2	2009	Photoexcitation of DMJ-An produces DMJ(+*)-An(-*) quantitatively, so that An(-*) acts as a high potential electron donor, which rapidly transfers an electron to NI yielding a long-lived spin-coherent radical ion pair (DMJ(+*)-An-Ph(n)-NI(-*)).	1-Deoxynojirimycin	35-38	spindlin 1	Homo sapiens	186-190
19426135-8	2009	In the presence of 1-deoxymannojirimycin, a drug which inhibits the generation of hybrid-type or complex type N-glycans, the extensively O-glycosylated mucin-like MUC1 glycoprotein was not delivered to the apical brush border but accumulated inside the cells.	1-Deoxynojirimycin	19-40	mucin 1, cell surface associated	Homo sapiens	163-167
19167250-6	2009	We report an increase in the activity of GBA using NN-DNJ, NB-DNJ and aminocyclitol 1 in stably transfected cell lines, and an increment with NN-DNJ and aminocyclitol 4 in patient fibroblasts.	1-Deoxynojirimycin	54-57	glucosylceramidase beta	Homo sapiens	41-44
19028522-4	2009	Pretreatment with 100 microM alpha-mannosidase inhibitor 1-deoxymannojirimycin (DMJ) in PC-12 cells significantly attenuated the cytotoxicity by ER stressors tunicamycin (TM), thapsigargin (TG), and amyloid beta1-42 (Abeta1-42), and reduced caspase-3 activation by TM and TG.	1-Deoxynojirimycin	57-78	caspase 3	Rattus norvegicus	241-250
19028522-4	2009	Pretreatment with 100 microM alpha-mannosidase inhibitor 1-deoxymannojirimycin (DMJ) in PC-12 cells significantly attenuated the cytotoxicity by ER stressors tunicamycin (TM), thapsigargin (TG), and amyloid beta1-42 (Abeta1-42), and reduced caspase-3 activation by TM and TG.	1-Deoxynojirimycin	80-83	caspase 3	Rattus norvegicus	241-250
19028522-6	2009	With regard to the effect of DMJ pretreatment on ER stress signaling in PC-12 cells, DMJ attenuated TM- and TG-induced CHOP expression and TG stimulated JNK phosphorylation, which is associated with ER stress dependent cell death.	1-Deoxynojirimycin	85-88	DNA-damage inducible transcript 3	Rattus norvegicus	119-123
18595718-4	2008	The potent GP inhibitor 1,4-dideoxy-1,4-imino-D-arabinitol (D-AB1) inhibited hepatic glucose production with an IC(50) value of about 9 microM and the inhibition by D-AB1 was further enhanced in the presence of DNJ.	1-Deoxynojirimycin	211-214	DAB adaptor protein 1	Homo sapiens	60-65
18595718-4	2008	The potent GP inhibitor 1,4-dideoxy-1,4-imino-D-arabinitol (D-AB1) inhibited hepatic glucose production with an IC(50) value of about 9 microM and the inhibition by D-AB1 was further enhanced in the presence of DNJ.	1-Deoxynojirimycin	211-214	DAB adaptor protein 1	Homo sapiens	165-170
18452013-1	2008	1-Deoxymannojirimycin (8c) was synthesised from 2-amino-6-bromo-2,6-dideoxy-D-mannono-1,4-lactone (7) by intramolecular direct displacement of the C-6 bromine employing non-aqueous base treatment followed by reduction of the intermediate methyl ester.	1-Deoxynojirimycin	0-21	complement C6	Homo sapiens	147-150
18166057-4	2008	The photoexcited charge transfer state of DMJ-An acts as a high-potential photoreductant to rapidly and nearly quantitatively transfer an electron across the Phn bridge to produce a spin-coherent singlet RP 1(DMJ+*-An-Phn-NI-*).	1-Deoxynojirimycin	42-45	carbamoyl-phosphate synthase 1	Homo sapiens	158-161
18166057-4	2008	The photoexcited charge transfer state of DMJ-An acts as a high-potential photoreductant to rapidly and nearly quantitatively transfer an electron across the Phn bridge to produce a spin-coherent singlet RP 1(DMJ+*-An-Phn-NI-*).	1-Deoxynojirimycin	42-45	carbamoyl-phosphate synthase 1	Homo sapiens	218-221
18166057-4	2008	The photoexcited charge transfer state of DMJ-An acts as a high-potential photoreductant to rapidly and nearly quantitatively transfer an electron across the Phn bridge to produce a spin-coherent singlet RP 1(DMJ+*-An-Phn-NI-*).	1-Deoxynojirimycin	209-212	carbamoyl-phosphate synthase 1	Homo sapiens	158-161
18166057-4	2008	The photoexcited charge transfer state of DMJ-An acts as a high-potential photoreductant to rapidly and nearly quantitatively transfer an electron across the Phn bridge to produce a spin-coherent singlet RP 1(DMJ+*-An-Phn-NI-*).	1-Deoxynojirimycin	209-212	carbamoyl-phosphate synthase 1	Homo sapiens	218-221
18166057-5	2008	Subsequent radical pair intersystem crossing yields 3(DMJ+*-An-Phn-NI-*).	1-Deoxynojirimycin	54-57	carbamoyl-phosphate synthase 1	Homo sapiens	63-66
18166057-7	2008	Time-resolved EPR spectroscopy shows directly that charge recombination of the RP initially produces a spin-polarized triplet state, DMJ-An-Phn-3*NI, that can only be produced by hole transfer involving the HOMOs of D, B, and A within the D-B-A system.	1-Deoxynojirimycin	133-136	carbamoyl-phosphate synthase 1	Homo sapiens	140-143
17621594-6	2007	The binding of PE-labeled sVIPL-SA was abrogated by endo beta-N-acetylglucosaminidase H treatment of the DMJ- or KIF-treated cells.	1-Deoxynojirimycin	105-108	O-GlcNAcase	Homo sapiens	57-85
17475258-0	2007	The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120.	1-Deoxynojirimycin	39-60	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	201-206
17217417-9	2007	Treatment of PC12 cells with 1-deoxymannojirimycin, a specific alpha-mannosidase I inhibitor, causes VMAT2 to localize to synaptic-like microvesicles.	1-Deoxynojirimycin	29-50	solute carrier family 18 member A2	Rattus norvegicus	101-106
17213836-2	2007	We studied the effects of two imino sugars, deoxynojirimycin (DNJ) and N-butyldeoxynojirimycin (NB-DNJ), on residual GAA activity in fibroblasts from eight patients with different forms of Pompe disease (two classic infantile, two non-classic infantile onset, four late-onset forms), and with different mutations of the GAA gene.	1-Deoxynojirimycin	62-65	alpha glucosidase	Homo sapiens	117-120
28182897-2	2007	We studied the effects of two imino sugars, deoxynojirimycin (DNJ) and N-butyldeoxynojirimycin (NB-DNJ), on residual GAA activity in fibroblasts from eight patients with different forms of Pompe disease (two classic infantile, two non-classic infantile onset, four late-onset forms), and with different mutations of the GAA gene.	1-Deoxynojirimycin	62-65	alpha glucosidase	Homo sapiens	117-120
17222224-3	2007	Previous studies showed that the disruption of early ER N-glycan processing by deoxynojirimycin (DNJ), an inhibitor of alpha-glucosidase, suppresses tyrosinase enzymatic activity and melanogenesis.	1-Deoxynojirimycin	79-95	sucrase-isomaltase	Homo sapiens	119-136
17222224-3	2007	Previous studies showed that the disruption of early ER N-glycan processing by deoxynojirimycin (DNJ), an inhibitor of alpha-glucosidase, suppresses tyrosinase enzymatic activity and melanogenesis.	1-Deoxynojirimycin	79-95	tyrosinase	Homo sapiens	149-159
17222224-3	2007	Previous studies showed that the disruption of early ER N-glycan processing by deoxynojirimycin (DNJ), an inhibitor of alpha-glucosidase, suppresses tyrosinase enzymatic activity and melanogenesis.	1-Deoxynojirimycin	97-100	sucrase-isomaltase	Homo sapiens	119-136
17222224-3	2007	Previous studies showed that the disruption of early ER N-glycan processing by deoxynojirimycin (DNJ), an inhibitor of alpha-glucosidase, suppresses tyrosinase enzymatic activity and melanogenesis.	1-Deoxynojirimycin	97-100	tyrosinase	Homo sapiens	149-159
17222224-5	2007	Following treatment of HM3KO human melanoma cells with deoxymannojirimycin (DMJ), an inhibitor of alpha-1,2-mannosidase, transport of tyrosinase to the melanosome, enzymatic activity, and melanogenesis were reduced in a dose-dependent manner.	1-Deoxynojirimycin	55-74	mannosidase alpha class 1A member 2	Homo sapiens	98-119
17222224-5	2007	Following treatment of HM3KO human melanoma cells with deoxymannojirimycin (DMJ), an inhibitor of alpha-1,2-mannosidase, transport of tyrosinase to the melanosome, enzymatic activity, and melanogenesis were reduced in a dose-dependent manner.	1-Deoxynojirimycin	55-74	tyrosinase	Homo sapiens	134-144
17222224-5	2007	Following treatment of HM3KO human melanoma cells with deoxymannojirimycin (DMJ), an inhibitor of alpha-1,2-mannosidase, transport of tyrosinase to the melanosome, enzymatic activity, and melanogenesis were reduced in a dose-dependent manner.	1-Deoxynojirimycin	76-79	mannosidase alpha class 1A member 2	Homo sapiens	98-119
17222224-5	2007	Following treatment of HM3KO human melanoma cells with deoxymannojirimycin (DMJ), an inhibitor of alpha-1,2-mannosidase, transport of tyrosinase to the melanosome, enzymatic activity, and melanogenesis were reduced in a dose-dependent manner.	1-Deoxynojirimycin	76-79	tyrosinase	Homo sapiens	134-144
17222224-7	2007	Interestingly, an extract of Streptomyces subrutilus culture medium (ESSCM) containing DMJ and DNJ as the main components inhibited glycosylation and transport of tyrosinase to the melanosome as well as melanin synthesis, but with no negative effects on cell viability.	1-Deoxynojirimycin	87-90	tyrosinase	Homo sapiens	163-173
17222224-7	2007	Interestingly, an extract of Streptomyces subrutilus culture medium (ESSCM) containing DMJ and DNJ as the main components inhibited glycosylation and transport of tyrosinase to the melanosome as well as melanin synthesis, but with no negative effects on cell viability.	1-Deoxynojirimycin	95-98	tyrosinase	Homo sapiens	163-173
17222224-9	2007	Tyrosinase glycosylation and melanogenesis in HM3KO melanoma cells were more effectively inhibited by DMJ and DNJ combined than DMJ or DNJ alone.	1-Deoxynojirimycin	102-105	tyrosinase	Homo sapiens	0-10
17222224-9	2007	Tyrosinase glycosylation and melanogenesis in HM3KO melanoma cells were more effectively inhibited by DMJ and DNJ combined than DMJ or DNJ alone.	1-Deoxynojirimycin	110-113	tyrosinase	Homo sapiens	0-10
17222224-9	2007	Tyrosinase glycosylation and melanogenesis in HM3KO melanoma cells were more effectively inhibited by DMJ and DNJ combined than DMJ or DNJ alone.	1-Deoxynojirimycin	128-131	tyrosinase	Homo sapiens	0-10
17222224-9	2007	Tyrosinase glycosylation and melanogenesis in HM3KO melanoma cells were more effectively inhibited by DMJ and DNJ combined than DMJ or DNJ alone.	1-Deoxynojirimycin	135-138	tyrosinase	Homo sapiens	0-10
17105727-7	2007	Hydrophobic deoxynojirimycins are extremely potent inhibitors for GBA2.	1-Deoxynojirimycin	12-29	glucosidase beta 2	Mus musculus	66-70
16806128-2	2006	Catalytic-domain crystal structures of yeast and human ERMan1s have been determined, the former with a hydrolytic product and the latter without ligands, with the inhibitors 1-deoxymannojirimycin and kifunensine, and with a thiodisaccharide substrate analog.	1-Deoxynojirimycin	174-195	mannosidase alpha class 1B member 1	Homo sapiens	55-61
16518858-6	2006	As expected, binding of TAA90K to galectin-3 was dependent on carbohydrate since it was inhibitable by lactose and asiolofetuin, and a TAA90K-His glycoform purified from HT-29 cells treated with the glycosylation inhibitor 1-deoxymannojirimycin bound poorly to galectin-3.	1-Deoxynojirimycin	223-244	galectin 3 binding protein	Homo sapiens	24-30
16518858-6	2006	As expected, binding of TAA90K to galectin-3 was dependent on carbohydrate since it was inhibitable by lactose and asiolofetuin, and a TAA90K-His glycoform purified from HT-29 cells treated with the glycosylation inhibitor 1-deoxymannojirimycin bound poorly to galectin-3.	1-Deoxynojirimycin	223-244	galectin 3	Homo sapiens	34-44
16615997-0	2006	1-Deoxymannojirimycin, the alpha1,2-mannosidase inhibitor, induced cellular endoplasmic reticulum stress in human hepatocarcinoma cell 7721.	1-Deoxynojirimycin	0-21	mannosidase alpha class 1A member 2	Homo sapiens	27-47
16615997-3	2006	In this study, 1-deoxymannojirimycin, a specific inhibitor of alpha1,2-mannosidase and generating "high mannose" type of N-glycan, was treated in human hepatocarcinoma 7721 cells and induced the endoplasmic reticulum stress.	1-Deoxynojirimycin	15-36	mannosidase alpha class 1A member 2	Homo sapiens	62-82
16528036-4	2006	alpha-Glucosidase inhibitors derived from the glucose analogue deoxynojirimycin (DNJ) inhibit viral morphogenesis in cellulo via perturbation of the N-glycosylation pathway and hence the misfolding of viral glycoproteins that depend on certain N-glycans for correct folding.	1-Deoxynojirimycin	63-79	sucrase-isomaltase	Homo sapiens	0-17
16528036-4	2006	alpha-Glucosidase inhibitors derived from the glucose analogue deoxynojirimycin (DNJ) inhibit viral morphogenesis in cellulo via perturbation of the N-glycosylation pathway and hence the misfolding of viral glycoproteins that depend on certain N-glycans for correct folding.	1-Deoxynojirimycin	81-84	sucrase-isomaltase	Homo sapiens	0-17
15771446-3	2005	Although d-DNJ and d-galacto-DNJ are known to be powerful competitive inhibitors of alpha-glucosidase and alpha-galactosidase, respectively, with K(i) values in the nM range, l-DNJ and l-galacto-DNJ were noncompetitive inhibitors of alpha-glucosidase and alpha-galactosidase, respectively, with K(i) values in the muM range.	1-Deoxynojirimycin	9-14	sucrase-isomaltase	Homo sapiens	84-101
15771446-3	2005	Although d-DNJ and d-galacto-DNJ are known to be powerful competitive inhibitors of alpha-glucosidase and alpha-galactosidase, respectively, with K(i) values in the nM range, l-DNJ and l-galacto-DNJ were noncompetitive inhibitors of alpha-glucosidase and alpha-galactosidase, respectively, with K(i) values in the muM range.	1-Deoxynojirimycin	9-14	sucrase-isomaltase	Homo sapiens	233-250
15128268-1	2004	Deoxynojirimycin (DNJ) analogues are inhibitors of ceramide glucosyltransferase (CGT), which catalyses the first step in the glucosphingolipid (GSL) biosynthetic pathway.	1-Deoxynojirimycin	0-16	UDP-glucose ceramide glucosyltransferase	Homo sapiens	51-79
15128268-1	2004	Deoxynojirimycin (DNJ) analogues are inhibitors of ceramide glucosyltransferase (CGT), which catalyses the first step in the glucosphingolipid (GSL) biosynthetic pathway.	1-Deoxynojirimycin	0-16	UDP-glucose ceramide glucosyltransferase	Homo sapiens	81-84
15128268-1	2004	Deoxynojirimycin (DNJ) analogues are inhibitors of ceramide glucosyltransferase (CGT), which catalyses the first step in the glucosphingolipid (GSL) biosynthetic pathway.	1-Deoxynojirimycin	18-21	UDP-glucose ceramide glucosyltransferase	Homo sapiens	51-79
15128268-1	2004	Deoxynojirimycin (DNJ) analogues are inhibitors of ceramide glucosyltransferase (CGT), which catalyses the first step in the glucosphingolipid (GSL) biosynthetic pathway.	1-Deoxynojirimycin	18-21	UDP-glucose ceramide glucosyltransferase	Homo sapiens	81-84
12952521-4	2003	The action of a deoxymannojirimycin- and kifunensine-sensitive alpha1,2-mannosidase was shown here to be required for both further glycan processing and progression of RI(332) in the ERAD pathway.	1-Deoxynojirimycin	16-35	mannosidase alpha class 1A member 2	Homo sapiens	63-83
14636047-7	2003	Differing conformations of 1-deoxymannojirimycin were also observed: a (4)C(1) and (1)C(4) conformation in dGMII and hERMI, respectively.	1-Deoxynojirimycin	27-48	alpha-Mannosidase class II a	Drosophila melanogaster	107-112
12560567-3	2003	Production of HIV in the presence of the mannosidase I inhibitor deoxymannojirimycin (dMM) significantly enhanced binding of HIV to MBL and increased MBL neutralization of an M-tropic HIV primary isolate.	1-Deoxynojirimycin	65-84	mannose binding lectin 2	Homo sapiens	132-135
12560567-3	2003	Production of HIV in the presence of the mannosidase I inhibitor deoxymannojirimycin (dMM) significantly enhanced binding of HIV to MBL and increased MBL neutralization of an M-tropic HIV primary isolate.	1-Deoxynojirimycin	65-84	mannose binding lectin 2	Homo sapiens	150-153
12560567-4	2003	In contrast, culturing HIV in the presence of alpha-glucosidase I and II inhibitors castanospermine and deoxynojirimycin only slightly affected virus binding and neutralization by MBL.	1-Deoxynojirimycin	104-120	mannose binding lectin 2	Homo sapiens	180-183
12502850-4	2003	Modulation of N-glycans on Env or GP through production of viruses in different primary cells or in the presence of the mannosidase I inhibitor deoxymannojirimycin dramatically affected DC-SIGN(R) infectivity enhancement.	1-Deoxynojirimycin	144-163	envelope protein	Simian immunodeficiency virus	27-30
11982484-9	2002	N-alkylated deoxynojirimycins (C(4)-C(18)) were evaluated for their inhibitory effects on ceramide-specific glucosyltransferase and glycoprotein-processing alpha-glucosidase.	1-Deoxynojirimycin	12-29	sucrase isomaltase (alpha-glucosidase)	Mus musculus	156-173
12051746-2	2002	We have previously shown that tyrosinase inhibition requires high NB-DNJ concentrations, suggesting an inefficient cellular uptake of the drug.	1-Deoxynojirimycin	69-72	tyrosinase	Mus musculus	30-40
12096925-6	2002	Treatment with DMM, a mannosidase inhibitor, efficiently reduced the appearance of high molecular weight forms of CD95 after IFN-gamma treatment, and sensitized SEM and REH cells to CD95-mediated death.	1-Deoxynojirimycin	15-18	Fas cell surface death receptor	Homo sapiens	114-118
12096925-6	2002	Treatment with DMM, a mannosidase inhibitor, efficiently reduced the appearance of high molecular weight forms of CD95 after IFN-gamma treatment, and sensitized SEM and REH cells to CD95-mediated death.	1-Deoxynojirimycin	15-18	interferon gamma	Homo sapiens	125-134
12096925-6	2002	Treatment with DMM, a mannosidase inhibitor, efficiently reduced the appearance of high molecular weight forms of CD95 after IFN-gamma treatment, and sensitized SEM and REH cells to CD95-mediated death.	1-Deoxynojirimycin	15-18	Fas cell surface death receptor	Homo sapiens	182-186
11772101-1	2002	[reaction: see text] Representative simple or polyhydroxylated, pyrrolidine (e.g, DRAM) or piperidine (e.g., DNJ) imines not only are potential carbohydrate-processing enzyme inhibitors that may be formed as regioisomeric variants but also are scaffolds that may be rapidly elaborated to diversely functionalized aza-sugars through highly diastereoselective organometallic additions.	1-Deoxynojirimycin	109-112	DNA damage regulated autophagy modulator 1	Homo sapiens	82-86
11752220-4	2002	To model virus-associated Env synthesized in the presence of DNM, native Env was expressed at the surface of mammalian cells treated with DNM.	1-Deoxynojirimycin	61-64	endogenous retrovirus group K member 20	Homo sapiens	73-76
11752220-4	2002	To model virus-associated Env synthesized in the presence of DNM, native Env was expressed at the surface of mammalian cells treated with DNM.	1-Deoxynojirimycin	138-141	endogenous retrovirus group K member 20	Homo sapiens	73-76
11752220-8	2002	These results are consistent with the inhibition by DNM of virus entry at the Env/coreceptor interaction step.	1-Deoxynojirimycin	52-55	endogenous retrovirus group K member 20	Homo sapiens	78-81
11752220-9	2002	Finally, preliminary data indicate that suboptimal concentrations of DNM and natural or synthetic CXCR4 ligands used in combination potently inhibit the Env-mediated membrane fusion process.	1-Deoxynojirimycin	69-72	endogenous retrovirus group K member 20	Homo sapiens	153-156
11406577-2	2001	The crystal structure of Drosophila Golgi alpha-mannosidase II in the absence and presence of the anti-cancer agent swainsonine and the inhibitor deoxymannojirimycin reveals a novel protein fold with an active site zinc intricately involved both in the substrate specificity of the enzyme and directly in the catalytic mechanism.	1-Deoxynojirimycin	146-165	alpha-Mannosidase class II a	Drosophila melanogaster	36-62
11223423-8	2001	The 24-h treatment of subcutaneous adipose tissue of a control subject with 1 mM 1-deoxymannojirimycin (dMM) caused the synthesis of active, but totally endo H-sensitive, LPL.	1-Deoxynojirimycin	81-102	lipoprotein lipase	Homo sapiens	171-174
11223423-8	2001	The 24-h treatment of subcutaneous adipose tissue of a control subject with 1 mM 1-deoxymannojirimycin (dMM) caused the synthesis of active, but totally endo H-sensitive, LPL.	1-Deoxynojirimycin	104-107	lipoprotein lipase	Homo sapiens	171-174
10995765-3	2000	Crystal structures of the catalytic domain of human ER class I alpha1,2-mannosidase have been determined both in the presence and absence of the potent inhibitors kifunensine and 1-deoxymannojirimycin.	1-Deoxynojirimycin	179-200	mannosidase alpha class 1A member 2	Homo sapiens	63-83
10764822-2	2000	As part of an overall effort to address this problem, we previously isolated a cDNA from Sf9 cells that encodes an insect alpha1,2-mannosidase (SfManI) which requires calcium and is inhibited by 1-deoxymannojirimycin.	1-Deoxynojirimycin	195-216	mannosidase alpha class 1A member 2	Homo sapiens	122-142
10537138-4	1999	On the other hand, the effects of other inhibitors, swainsonine and deoxymannojirimycin, were much lower, suggesting that the high mannose-type carbohydrate side-chain is essential to the expression of a fully functional hSR.	1-Deoxynojirimycin	68-87	HSR	Homo sapiens	221-224
10521544-4	1999	Calcium is required for enzyme activity and both 1-deoxymannojirimycin and kifunensine inhibit the human alpha 1,2-mannosidase.	1-Deoxynojirimycin	49-70	mannosidase alpha class 1A member 2	Homo sapiens	105-126
10364189-10	1999	These associations were inhibited in vivo by deoxynojirimycin, an inhibitor of N-glycan precusor trimming that is known to prevent the calnexin/calreticulin-N-glycan interaction.	1-Deoxynojirimycin	45-61	calnexin	Homo sapiens	135-143
10364189-10	1999	These associations were inhibited in vivo by deoxynojirimycin, an inhibitor of N-glycan precusor trimming that is known to prevent the calnexin/calreticulin-N-glycan interaction.	1-Deoxynojirimycin	45-61	calreticulin	Homo sapiens	144-156
9756888-0	1998	Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase.	1-Deoxynojirimycin	23-39	glucosylceramidase beta 2	Homo sapiens	63-95
9756888-7	1998	The inhibitors were designed on the basis of the known features of the non-lysosomal glucosylceramidase and consist of a DNM moiety, an N-alkyl spacer, and a large hydrophobic group that promotes insertion in membranes.	1-Deoxynojirimycin	121-124	glucosylceramidase beta 2	Homo sapiens	71-103
9557712-5	1998	An increase of cellular oligomannosyl receptors by incubation with the mannosidase inhibitor deoxymannojirimycin augmented transcellular transport of the gp120-coated particles.	1-Deoxynojirimycin	93-112	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	154-159
9454727-1	1998	The influence of HIV Env glycosylation on the conformation of the third variable domain (V3) of Env was studied by both deglycosylation of mature Env and the use of Env produced by recombinant systems in which alpha-glucosidase activity was inhibited by either deoxynojirimycin (DNM) or mutation.	1-Deoxynojirimycin	261-277	endogenous retrovirus group K member 20	Homo sapiens	96-99
9454727-1	1998	The influence of HIV Env glycosylation on the conformation of the third variable domain (V3) of Env was studied by both deglycosylation of mature Env and the use of Env produced by recombinant systems in which alpha-glucosidase activity was inhibited by either deoxynojirimycin (DNM) or mutation.	1-Deoxynojirimycin	261-277	endogenous retrovirus group K member 20	Homo sapiens	96-99
9454727-1	1998	The influence of HIV Env glycosylation on the conformation of the third variable domain (V3) of Env was studied by both deglycosylation of mature Env and the use of Env produced by recombinant systems in which alpha-glucosidase activity was inhibited by either deoxynojirimycin (DNM) or mutation.	1-Deoxynojirimycin	279-282	endogenous retrovirus group K member 20	Homo sapiens	96-99
9454727-1	1998	The influence of HIV Env glycosylation on the conformation of the third variable domain (V3) of Env was studied by both deglycosylation of mature Env and the use of Env produced by recombinant systems in which alpha-glucosidase activity was inhibited by either deoxynojirimycin (DNM) or mutation.	1-Deoxynojirimycin	279-282	endogenous retrovirus group K member 20	Homo sapiens	96-99
9454727-3	1998	The immunoreactivity and sensitivity to thrombin cleavage of V3 presented on Env produced in baby hamster kidney cells were changed by DNM treatment.	1-Deoxynojirimycin	135-138	endogenous retrovirus group K member 20	Homo sapiens	77-80
9454727-4	1998	In contrast, Env expressed in alpha-glucosidase I-deficient Chinese hamster ovary cells or in their parental cells treated by DNM fully retained these V3 properties.	1-Deoxynojirimycin	126-129	endogenous retrovirus group K member 20	Homo sapiens	13-16
9271078-3	1997	Inhibition of glucosidase I and II with castanospermine or alpha-1,2-mannosidase with 1-deoxymannojirimycin produced altered ER processing intermediates that were rapidly secreted.	1-Deoxynojirimycin	86-107	mannosyl-oligosaccharide glucosidase	Homo sapiens	14-27
9271078-3	1997	Inhibition of glucosidase I and II with castanospermine or alpha-1,2-mannosidase with 1-deoxymannojirimycin produced altered ER processing intermediates that were rapidly secreted.	1-Deoxynojirimycin	86-107	mannosidase alpha class 1A member 2	Homo sapiens	59-80
9219849-7	1997	Furthermore, the modification of N-glycan on CEA by deoxymannojirimycin, an N-glycosylation processing inhibitor, partially restored ADR sensitivity of CEA transfectants, suggesting an involvement of sugar chains.	1-Deoxynojirimycin	52-71	carcinoembryonic antigen gene family	Mus musculus	45-48
9219849-7	1997	Furthermore, the modification of N-glycan on CEA by deoxymannojirimycin, an N-glycosylation processing inhibitor, partially restored ADR sensitivity of CEA transfectants, suggesting an involvement of sugar chains.	1-Deoxynojirimycin	52-71	carcinoembryonic antigen gene family	Mus musculus	152-155
22358530-5	1997	Treatment of filter-grown MDCK cells with glycosylation inhibitors, swainsonine and 1-deoxymannojirimycin, appeared to enhance the apical secretion of tyrosine-sulfated FN and gp 80.	1-Deoxynojirimycin	84-105	clusterin	Canis lupus familiaris	176-181
9003768-4	1996	When expressed with two N-linked glycans in the presence of micromolar concentrations of deoxynojirimycin, this small soluble protein was found to bind firmly to both calnexin and calreticulin.	1-Deoxynojirimycin	89-105	calnexin	Bos taurus	167-175
9003768-4	1996	When expressed with two N-linked glycans in the presence of micromolar concentrations of deoxynojirimycin, this small soluble protein was found to bind firmly to both calnexin and calreticulin.	1-Deoxynojirimycin	89-105	calreticulin	Bos taurus	180-192
8856072-5	1996	Methyl alpha-D-mannoside and 1-deoxymannojirimycin were also competitive inhibitors of trehalase and competed with each other for the same site.	1-Deoxynojirimycin	29-50	trehalase	Sus scrofa	87-96
8601595-4	1996	In contrast, treatment of the same cells with deoxymannojirimycin, which inhibits the conversion of high mannose oligosaccharides to complex N-linked carbohydrates, results in either no change or an increase in CD44-mediated adhesion to hyaluronate, suggesting that complex N-linked oligosaccharides may not be required for and may even inhibit CD44-HA interaction.	1-Deoxynojirimycin	46-65	CD44 molecule (Indian blood group)	Homo sapiens	211-215
8601595-4	1996	In contrast, treatment of the same cells with deoxymannojirimycin, which inhibits the conversion of high mannose oligosaccharides to complex N-linked carbohydrates, results in either no change or an increase in CD44-mediated adhesion to hyaluronate, suggesting that complex N-linked oligosaccharides may not be required for and may even inhibit CD44-HA interaction.	1-Deoxynojirimycin	46-65	CD44 molecule (Indian blood group)	Homo sapiens	345-349
8621356-3	1996	Nojirimycin A, nojirimycin B, deoxynojirimycin and D-gluco-delta-lactam showed potent or moderate inhibitory activities against alpha-glucosidase, beta-glucosidase and beta-mannosidase, but CP3068 and CP3069 in which the structures were related to D-gluco-delta-lactam showed no inhibitory activities.	1-Deoxynojirimycin	30-46	sucrase isomaltase (alpha-glucosidase)	Mus musculus	128-145
8621356-3	1996	Nojirimycin A, nojirimycin B, deoxynojirimycin and D-gluco-delta-lactam showed potent or moderate inhibitory activities against alpha-glucosidase, beta-glucosidase and beta-mannosidase, but CP3068 and CP3069 in which the structures were related to D-gluco-delta-lactam showed no inhibitory activities.	1-Deoxynojirimycin	30-46	mannosidase, beta A, lysosomal	Mus musculus	168-184
7496154-5	1995	Finally, when melanoma cells are treated with inhibitors of carbohydrate processing, such as N-methyl-1-deoxynojirimycin, 1-deoxymannojirimycin and swainsonine, they still secrete a motility-stimulating autotaxin.	1-Deoxynojirimycin	122-143	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	203-212
7618283-8	1995	In the presence of DMJ, a mannosidase I inhibitor, MCP is synthesized with N-glycans of the high-mannose type in contrast to the complex oligosaccharides present on MCP of untreated cells.	1-Deoxynojirimycin	19-22	CD46 molecule	Homo sapiens	51-54
7618283-8	1995	In the presence of DMJ, a mannosidase I inhibitor, MCP is synthesized with N-glycans of the high-mannose type in contrast to the complex oligosaccharides present on MCP of untreated cells.	1-Deoxynojirimycin	19-22	CD46 molecule	Homo sapiens	165-168
7864639-7	1995	A number of other glucosidase inhibitors, such as MDL 25637, castanospermine, and deoxynojirimycin were also tested against the purified trehalase and showed reasonable inhibitory activity.	1-Deoxynojirimycin	82-98	trehalase	Sus scrofa	137-146
7811745-8	1995	LPL in cells treated with deoxymannojirimycin, an inhibitor of Golgi mannosidase I, was active, dimeric, and had high affinity for heparin as in normal cells.	1-Deoxynojirimycin	26-45	lipoprotein lipase	Homo sapiens	0-3
7873926-5	1994	S-MBP bound to the dMM-treated BHK cells in the presence of Ca2+, and this binding was eliminated by mannose.	1-Deoxynojirimycin	19-22	transmembrane 9 superfamily member 3	Homo sapiens	0-5
7873926-6	1994	When dMM-treated cells, labelled with 51Cr, were incubated with complement, radioactivity was released in a dose-dependent manner by S-MBP and complement.	1-Deoxynojirimycin	5-8	transmembrane 9 superfamily member 3	Homo sapiens	133-138
8054362-7	1994	In the presence of 1 mM dMM, cells synthesized Endo H-sensitive alpha 2-PI and ATIII with similar secretion rates.	1-Deoxynojirimycin	24-27	serpin family F member 2	Homo sapiens	64-74
8054362-7	1994	In the presence of 1 mM dMM, cells synthesized Endo H-sensitive alpha 2-PI and ATIII with similar secretion rates.	1-Deoxynojirimycin	24-27	serpin family C member 1	Homo sapiens	79-84
8155721-4	1994	In contrast, as in untreated cells, LPL subunits in 1-deoxymannojirimycin (dMM)-treated and swainsonine (SW)-treated cells almost all bound to the column and over 93% of the subunits bound were eluted with 1.5 M NaCl.	1-Deoxynojirimycin	52-73	lipoprotein lipase	Homo sapiens	36-39
8155721-4	1994	In contrast, as in untreated cells, LPL subunits in 1-deoxymannojirimycin (dMM)-treated and swainsonine (SW)-treated cells almost all bound to the column and over 93% of the subunits bound were eluted with 1.5 M NaCl.	1-Deoxynojirimycin	75-78	lipoprotein lipase	Homo sapiens	36-39
8116232-3	1994	By applying inhibitors of the glycosylation pathway (deoxymannojirimycin and swainsonine) we were able to monitor the modification of the hPVR glycoproteins when passing through the processing pathway.	1-Deoxynojirimycin	53-72	PVR cell adhesion molecule	Homo sapiens	138-142
8099781-9	1993	(iv) Treatment with deoxymannojirimycin resulted in the synthesis of Thy-1 that contained Man8 and Man9 oligosaccharides compared to Man5, Man6, and Man7 in the control.	1-Deoxynojirimycin	20-39	Thy-1 cell surface antigen	Rattus norvegicus	69-74
8314518-7	1993	Pretreatment of human colon adenocarcinoma derived HT-29 cells with DMJ resulted in an expression of the 105 kD beta 1 precursor chain and of smaller forms of the alpha 1, alpha 3, alpha 6, and alpha v integrin subunits in a time and dose dependent manner.	1-Deoxynojirimycin	68-71	adrenoceptor alpha 1D	Homo sapiens	163-188
8314518-8	1993	HT-29 cells treated with DMJ adhered poorly to laminin (8% of untreated controls), collagen type IV (40%), and fibronectin (35%).	1-Deoxynojirimycin	25-28	fibronectin 1	Homo sapiens	111-122
8314518-9	1993	Pretreatment of the cells with DNJ did not alter the molecular weight of the integrin chains expressed and reduced HT-29 adhesion to laminin and fibronectin only to 68% and 49% respectively.	1-Deoxynojirimycin	31-34	fibronectin 1	Homo sapiens	145-156
8454617-4	1993	To test this hypothesis, glucosidase I was purified from the rat mammary gland and its active site was loaded with 1-deoxynojirimycin, to protect such a group(s), while -SH groups on the remaining surface of the enzyme were blocked with N-ethylmaleimide or para-chloromercuriphenylsulfonic acid.	1-Deoxynojirimycin	115-133	mannosyl-oligosaccharide glucosidase	Homo sapiens	25-38
8457606-7	1993	Non-lysosomal glucocerebrosidase proved to be less sensitive to inhibition by castanospermine or deoxynojirimycin but more sensitive to inhibition by D-gluconolactone than the lysosomal glucocerebrosidase.	1-Deoxynojirimycin	97-113	glucosylceramidase beta	Homo sapiens	4-32
8501138-5	1993	Similarly, IL-1 treatment resulted in a beta 2 integrin mediated increase in neutrophil adherence to the DMJ treated endothelial cells in a dose dependent manner.	1-Deoxynojirimycin	105-108	interleukin 1 beta	Homo sapiens	11-15
8501138-5	1993	Similarly, IL-1 treatment resulted in a beta 2 integrin mediated increase in neutrophil adherence to the DMJ treated endothelial cells in a dose dependent manner.	1-Deoxynojirimycin	105-108	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	40-46
8431454-6	1993	Adding tunicamycin or deoxymannojirimycin to the TGF-beta 1-treated and untreated cells caused these 55 and 65 kDa glucose transporters to migrate as one band at 40-43 kDa.	1-Deoxynojirimycin	22-41	transforming growth factor, beta 1	Mus musculus	49-59
8381403-10	1993	Furthermore, WGA inhibition was not abolished although most, if not all, VIP receptor oligosaccharides were converted to high mannose type structures by treating IGR39 cells with deoxymannojirimycin.	1-Deoxynojirimycin	179-198	vasoactive intestinal peptide	Homo sapiens	73-76
8440752-5	1993	1-deoxymannojirimycin (MNJ), which is an inhibitor of oligosaccharide processing, induced disorganization of the extracellular matrix fibronectin assembly similar to that observed with retinyl acetate.	1-Deoxynojirimycin	0-21	fibronectin 1	Mus musculus	134-145
8433710-2	1993	Treatment using the glycosylation processing inhibitors, castanospermine (CN), 1-deoxymannojirimycin (DMJ), and swainsonine (SW) resulted in a decrease of the relative molecular mass (M(r)) of both the alpha-chain of the high affinity receptor for IgE, Fc epsilon RI(alpha), and the low affinity receptor for IgE, Fc epsilon RL.	1-Deoxynojirimycin	79-100	Fc epsilon receptor Ia	Rattus norvegicus	253-272
8433710-2	1993	Treatment using the glycosylation processing inhibitors, castanospermine (CN), 1-deoxymannojirimycin (DMJ), and swainsonine (SW) resulted in a decrease of the relative molecular mass (M(r)) of both the alpha-chain of the high affinity receptor for IgE, Fc epsilon RI(alpha), and the low affinity receptor for IgE, Fc epsilon RL.	1-Deoxynojirimycin	102-105	Fc epsilon receptor Ia	Rattus norvegicus	253-272
8380585-6	1993	Forms of alpha 1-AT identical to those retained with ionomycin or thapsigargin were observed upon treatment with the alpha-1,2-mannosidase inhibitor 1-deoxymannojirimycin whereas castanospermine, an inhibitor of ER alpha-glucosidase I, produced different forms of the glycoprotein.	1-Deoxynojirimycin	149-170	serpin family A member 1	Homo sapiens	9-19
8380585-8	1993	With brefeldin A, which causes redistribution of Golgi enzymes to the ER, alpha 1-AT was retained intracellularly but acquired resistance to Endo H. With ionomycin, thapsigargin, or 1-deoxymannojirimycin-treated cells, however, brefeldin A failed to promote further processing of the glycoprotein.	1-Deoxynojirimycin	184-203	serpin family A member 1	Homo sapiens	74-84
8416996-3	1993	Transport and phosphorylation of the CI-MPR in the biosynthetic pathway were examined using deoxymannojirimycin (dMM), a specific inhibitor of the cis-Golgi processing enzyme alpha-mannosidase I which leads to the accumulation of N-linked high mannose oligosaccharides on glycoproteins.	1-Deoxynojirimycin	92-111	insulin like growth factor 2 receptor	Bos taurus	37-43
1479287-10	1992	In the presence of castanospermine and DMJ, the half-life of newly synthesized LPL was increased to 81 and 113 min, as compared to 65 min in control cells.	1-Deoxynojirimycin	39-42	lipoprotein lipase	Rattus norvegicus	79-82
1359965-8	1992	DPP IV molecules were very slowly degraded in hepatocytes as well as in hepatoma cells with half-lives of approximately 45 h. Inhibition of oligosaccharide processing with 1-deoxymannojirimycin led to the formation of DPP IV molecules containing N-glycans of the oligomannosidic type.	1-Deoxynojirimycin	174-193	dipeptidylpeptidase 4	Rattus norvegicus	0-6
1359965-8	1992	DPP IV molecules were very slowly degraded in hepatocytes as well as in hepatoma cells with half-lives of approximately 45 h. Inhibition of oligosaccharide processing with 1-deoxymannojirimycin led to the formation of DPP IV molecules containing N-glycans of the oligomannosidic type.	1-Deoxynojirimycin	174-193	dipeptidylpeptidase 4	Rattus norvegicus	218-224
1373727-9	1992	When grown in the presence of 1-deoxymannojirimycin, the C5b-9-inhibitory activity of CD59 expressed on the surface of the transfected CHO cells was reduced by an amount comparable to that observed for the N-glycanase digested protein.	1-Deoxynojirimycin	30-51	CD59 glycoprotein	Cricetulus griseus	86-90
1532183-3	1992	Tyrosinase in CS- and dNM-treated cells showed 50% loss of activity within 5 h but recovered rapidly when the drugs were removed; dMN and SW had little effect.	1-Deoxynojirimycin	22-25	tyrosinase	Homo sapiens	0-10
1532183-4	1992	Expression of the tyrosinase 2B7 epitope and of an 80-kDa melanosomal antigen (B8G3) was inhibited by TM but not by CS, dNM, dMM, or SW. CS and dNM appeared to decrease the half-life of active tyrosinase.	1-Deoxynojirimycin	144-147	tyrosinase	Homo sapiens	18-28
1556130-8	1992	LPL was active and secreted when trimming of the mannose residues was inhibited by deoxymannojirimycin and when addition of complex sugars was blocked using Chinese hamster ovary mutants (lec1 and lec2), indicating that these processing events are not necessary for the expression of a functional enzyme.	1-Deoxynojirimycin	83-102	LOW QUALITY PROTEIN: lipoprotein lipase	Cricetulus griseus	0-3
1531012-4	1992	Studies on cells cultured in the presence of drugs known to affect the intracellular transport (deoxynojirimycin, brefeldin A and NH4Cl) indicated that the association with cathepsin D precursor occurs early after the synthesis and is at least partially maintained after secretion.	1-Deoxynojirimycin	96-112	cathepsin D	Homo sapiens	173-184
1834650-5	1991	In the presence of 1-deoxymannojirimycin, a specific inhibitor of alpha-mannosidase I, differentiated HT-29 cells, as expected, accumulate Man9-8-GlcNAc2 species, whereas in undifferentiated HT-29 cells these compounds continue to be rapidly degraded.	1-Deoxynojirimycin	19-40	mannosidase alpha class 1A member 1	Homo sapiens	139-143
1654885-2	1991	Human melanoma IGR 39 cells, incubated for 60 h with the inhibitors tunicamycin, castanospermine, swainsonine or deoxymannojirimycin, under conditions where cell viability and protein synthesis were not affected, expressed VIP receptor species with different VIP-binding properties.	1-Deoxynojirimycin	113-132	vasoactive intestinal peptide	Homo sapiens	223-226
1654885-3	1991	The most pronounced effects on VIP binding were obtained with tunicamycin and deoxymannojirimycin, which respectively caused 80% and 67% inhibition.	1-Deoxynojirimycin	78-97	vasoactive intestinal peptide	Homo sapiens	31-34
1654885-5	1991	Based on Scatchard analyses of data from competition experiments, the decrease in VIP-binding activity in either swainsonine- or deoxymannojirimycin-treated cells was due to a decrease in ligand affinity; the cell-surface number of VIP-binding sites remained unchanged.	1-Deoxynojirimycin	129-148	vasoactive intestinal peptide	Homo sapiens	82-85
1654885-5	1991	Based on Scatchard analyses of data from competition experiments, the decrease in VIP-binding activity in either swainsonine- or deoxymannojirimycin-treated cells was due to a decrease in ligand affinity; the cell-surface number of VIP-binding sites remained unchanged.	1-Deoxynojirimycin	129-148	vasoactive intestinal peptide	Homo sapiens	232-235
1654885-8	1991	When compared with their counterpart synthesized in control cells, VIP-binding proteins produced by deoxymannojirimycin- or swainsonine-treated cells were smaller in size and exhibited the expected sensitivity to Endo H. No modification in the apparent molecular mass was observed in the presence of either castanospermine or tunicamycin.	1-Deoxynojirimycin	100-119	vasoactive intestinal peptide	Homo sapiens	67-70
1831351-11	1991	Blocking either Golgi mannosidase I with 4 mM-1-deoxymannojirimycin or Golgi mannosidase II with 10 microM-swainsonine resulted in production of a form of lipoprotein lipase which was active and secreted, and which contained only endo H-sensitive chains.	1-Deoxynojirimycin	46-67	lipoprotein lipase	Mus musculus	155-173
1716973-9	1991	1-Deoxymannojirimycin and Swainsonine, which block glycosylation at the high-mannose and hybrid-type stages respectively, modulated the CD22 antigen but did not alter its surface expression.	1-Deoxynojirimycin	0-21	CD22 molecule	Homo sapiens	136-140
1710120-11	1991	However, incubation of cells with castanospermine-6-butyrate or deoxymannojirimycin decreased cell surface ICAM-1 levels only slightly.	1-Deoxynojirimycin	64-83	intercellular adhesion molecule 1	Homo sapiens	107-113
1828762-10	1991	Further analyses using glycoprotein synthesis inhibitors showed that N-linked processing of the alpha-chain, especially glucose removal by glucosidase I and II (whose activities are inhibited by deoxynojirimycin), appeared to be required for the expression onto the cell surface although the beta-chain expression was little affected by their inhibitors.	1-Deoxynojirimycin	195-211	Fc gamma receptor and transporter	Homo sapiens	96-107
1828762-10	1991	Further analyses using glycoprotein synthesis inhibitors showed that N-linked processing of the alpha-chain, especially glucose removal by glucosidase I and II (whose activities are inhibited by deoxynojirimycin), appeared to be required for the expression onto the cell surface although the beta-chain expression was little affected by their inhibitors.	1-Deoxynojirimycin	195-211	mannosyl-oligosaccharide glucosidase	Homo sapiens	139-159
2400992-10	1990	Both deoxymannojirimycin and swainsonine, inhibitors of glycoprotein processing, raise intracellular levels of Man5-9GlcNAc2 and enhance the in vitro biological activity of both rTNF and rIL-1.	1-Deoxynojirimycin	5-24	tumor necrosis factor	Rattus norvegicus	178-182
2150412-8	1990	Upon SDS-polyacrylamide gel electrophoresis, hepatic lipase secretion by deoxymannojirimycin- or swainsonine-treated cells showed an apparent Mr of 53 kDa and 55 kDa, respectively, which was distinct from hepatic lipase secreted by untreated cells (Mr = 58 kDa).	1-Deoxynojirimycin	73-92	lipase C, hepatic type	Rattus norvegicus	45-59
2150412-8	1990	Upon SDS-polyacrylamide gel electrophoresis, hepatic lipase secretion by deoxymannojirimycin- or swainsonine-treated cells showed an apparent Mr of 53 kDa and 55 kDa, respectively, which was distinct from hepatic lipase secreted by untreated cells (Mr = 58 kDa).	1-Deoxynojirimycin	73-92	lipase C, hepatic type	Rattus norvegicus	205-219
2135400-6	1990	Other studies show that EGF accelerates at least two slow events in receptor maturation--the deoxynojirimycin sensitive processing in endoplasmic reticulum (ER) and the swainsonine sensitive processing in Golgi.	1-Deoxynojirimycin	93-109	epidermal growth factor	Homo sapiens	24-27
2165493-5	1990	We have found that in the presence of the glucosidase inhibitors, castanospermine (CST) or 1-deoxynojirimycin, there is a substantial production of the glucosylated mannose saccharides (Glc3Man, Glc2Man, and Glc1Man) which are the characteristic products of endomannosidase action.	1-Deoxynojirimycin	91-109	mannosidase endo-alpha	Homo sapiens	258-273
2114451-5	1990	In the large granule fraction, a recovery of membrane-bound tyrosinase (T3) is seen following both MS and SW treatments, whereas dNM treatment results in the substantial loss of T3 tyrosinase.	1-Deoxynojirimycin	129-132	tyrosinase	Mus musculus	181-191
2114451-6	1990	At the electron microscopic level, a translocation of tyrosinase from GERL and coated vesicles to many unmelanized vacuolar premelanosomes occurs in MS-treated cells in contrast to its predominant distribution in the GERL-coated vesicle system of dNM-treated cells, which contain many unmelanized premelanosomes.	1-Deoxynojirimycin	247-250	tyrosinase	Mus musculus	54-64
2113058-7	1990	By comparing IgM made in the presence and absence of deoxymannojirimycin, we show further that the defect in cytolytic activity derives mostly from the abnormal oligosaccharide.	1-Deoxynojirimycin	53-72	immunoglobulin heavy constant mu	Mus musculus	13-16
2137773-0	1990	Effects of deoxymannojirimycin and castanospermine on the polarized secretion of thyroglobulin.	1-Deoxynojirimycin	11-30	thyroglobulin	Homo sapiens	81-94
2406237-5	1990	Evidence is presented that gp160 is subject to mannose trimming in the Golgi complex, which is inhibited by 1-deoxymannojirimycin (a specific Golgi alpha-mannosidase I inhibitor).	1-Deoxynojirimycin	108-129	glutamyl aminopeptidase	Homo sapiens	27-32
34870992-3	2021	Iminosugars based on deoxynojirimycin have been extensively studied as ER alpha-glucosidase inhibitors; however, other glycomimetic compounds are less established.	1-Deoxynojirimycin	21-37	estrogen receptor 1 (alpha)	Mus musculus	71-79
35077826-12	2022	Mechanistically, DNJ treatment suppressed the circulating levels of LPS, IL-6, and TNF-alpha in plasma and decreased the inflammatory infiltration in liver and colon tissues.	1-Deoxynojirimycin	17-20	interleukin 6	Mus musculus	73-77
35077826-12	2022	Mechanistically, DNJ treatment suppressed the circulating levels of LPS, IL-6, and TNF-alpha in plasma and decreased the inflammatory infiltration in liver and colon tissues.	1-Deoxynojirimycin	17-20	tumor necrosis factor	Mus musculus	83-92
35072486-3	2022	This study provides the first example of a strategy to design a high-affinity ligand toward lysosomal acid alpha-glucosidase (GAA) focusing on alkyl branches on 1-deoxynojirimycin (DNJ); 5-C-heptyl-DNJ produced a nanomolar affinity for GAA with a Ki value of 0.0047 muM, which is 13-fold more potent than DNJ.	1-Deoxynojirimycin	161-179	alpha glucosidase	Homo sapiens	126-129
35072486-3	2022	This study provides the first example of a strategy to design a high-affinity ligand toward lysosomal acid alpha-glucosidase (GAA) focusing on alkyl branches on 1-deoxynojirimycin (DNJ); 5-C-heptyl-DNJ produced a nanomolar affinity for GAA with a Ki value of 0.0047 muM, which is 13-fold more potent than DNJ.	1-Deoxynojirimycin	161-179	alpha glucosidase	Homo sapiens	236-239
35072486-3	2022	This study provides the first example of a strategy to design a high-affinity ligand toward lysosomal acid alpha-glucosidase (GAA) focusing on alkyl branches on 1-deoxynojirimycin (DNJ); 5-C-heptyl-DNJ produced a nanomolar affinity for GAA with a Ki value of 0.0047 muM, which is 13-fold more potent than DNJ.	1-Deoxynojirimycin	181-184	alpha glucosidase	Homo sapiens	126-129
35072486-3	2022	This study provides the first example of a strategy to design a high-affinity ligand toward lysosomal acid alpha-glucosidase (GAA) focusing on alkyl branches on 1-deoxynojirimycin (DNJ); 5-C-heptyl-DNJ produced a nanomolar affinity for GAA with a Ki value of 0.0047 muM, which is 13-fold more potent than DNJ.	1-Deoxynojirimycin	181-184	alpha glucosidase	Homo sapiens	236-239
2530217-1	1989	1-Deoxymannojirimycin (MNJ), an inhibitor of Golgi alpha-mannosidase IA and IB, was used to assess the possible roles of asparagine-linked oligosaccharides in the structure and function of the integrin fibronectin receptor from cultured human fibroblasts.	1-Deoxynojirimycin	0-21	fibronectin 1	Homo sapiens	202-213
2480355-3	1989	Conversely, the vitronectin receptor synthesized in the presence of the mannosidase I and II inhibitors, 1-deoxymannojirimycin and swainsonine, was transported normally to the cell surface with its alpha chain N-linked oligosaccharides in an endoglycosidase H-sensitive form.	1-Deoxynojirimycin	105-126	vitronectin	Homo sapiens	16-27
2677679-3	1989	1-Deoxymannojirimycin and swainsonine, inhibitors of the mannosidases I and II, respectively, blocked complete glycoprotein processing of the TGF-beta 1 precursor as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and by sensitivity to glycosidases.	1-Deoxynojirimycin	0-21	transforming growth factor beta-1 proprotein	Cricetulus griseus	142-152
2677679-5	1989	In contrast, inhibitors of the glucosidases at the first step in glycoprotein remodeling, 1-deoxynojirimycin and castanospermine, markedly inhibited secretion of the TGF-beta 1 polypeptides from transfected CHO cells.	1-Deoxynojirimycin	90-108	transforming growth factor beta-1 proprotein	Cricetulus griseus	166-176
2524494-3	1989	Furthermore, alpha 1-antitrypsin secreted by HepG2 cells was modified indistinguishably by treatment of the cells with dMM and 1-[3H]dMM.	1-Deoxynojirimycin	119-122	serpin family A member 1	Homo sapiens	13-32
2541446-3	1989	Deoxynojirimycin, an inhibitor of glucosidase I in the rough endoplasmic reticulum, inhibited the proteolytic processing of gp160, whereas no such effect was noted with either deoxymannojirimycin or swainsonine, inhibitors of mannosidase I and II, respectively, in the Golgi complex.	1-Deoxynojirimycin	0-16	mannosyl-oligosaccharide glucosidase	Homo sapiens	34-47
2541446-3	1989	Deoxynojirimycin, an inhibitor of glucosidase I in the rough endoplasmic reticulum, inhibited the proteolytic processing of gp160, whereas no such effect was noted with either deoxymannojirimycin or swainsonine, inhibitors of mannosidase I and II, respectively, in the Golgi complex.	1-Deoxynojirimycin	0-16	glutamyl aminopeptidase	Homo sapiens	124-129
2541446-4	1989	The processed gp120 and gp41 synthesized in the presence of deoxymannojirimycin were found to contain mannose-rich oligosaccharide cores as evidenced by their susceptibility to endoglycosidase H digestion.	1-Deoxynojirimycin	60-79	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	14-19
16666667-6	1989	Treatment with dMM fully inhibited the acquisition of resistance to endo-beta-N-acetylglucosaminidase H by phaseolin and phytohemagglutinin and the incorporation of fucose into protein.	1-Deoxynojirimycin	15-18	O-GlcNAcase	Homo sapiens	73-101
2521859-9	1989	Cells treated with methyl-deoxynojirimycin or with deoxymannojirimycin produced and released active lipoprotein lipase which was fully Endo H-sensitive.	1-Deoxynojirimycin	51-70	lipoprotein lipase	Cavia porcellus	100-118
2542177-2	1989	In Molt3 cells infected with human T-lymphotropic virus type III (HTLV-IIIB), DNM inhibited the intracellular proteolytic processing of gp160 to gp120 and gp41.	1-Deoxynojirimycin	78-81	glutamyl aminopeptidase	Homo sapiens	136-141
2542177-2	1989	In Molt3 cells infected with human T-lymphotropic virus type III (HTLV-IIIB), DNM inhibited the intracellular proteolytic processing of gp160 to gp120 and gp41.	1-Deoxynojirimycin	78-81	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	145-150
2542177-6	1989	These secreted glycoproteins from DNM-treated cells exhibited specific interaction with the CD4 molecule on the surface of target cells.	1-Deoxynojirimycin	34-37	CD4 molecule	Homo sapiens	92-95
3264072-3	1988	The electrophoretic mobility of gp120 was decreased when gp120 was synthesized in the presence of castanospermine or 1-deoxynojirimycin (inhibitors of glucosidase I), increased when gp120 was synthesized in the presence of 1-deoxymannojirimycin (mannosidase I) or swainsonine (mannosidase II), and unaffected when gp120 was synthesized in the presence of bromoconduritol (glucosidase II).	1-Deoxynojirimycin	117-135	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	32-37
3264072-3	1988	The electrophoretic mobility of gp120 was decreased when gp120 was synthesized in the presence of castanospermine or 1-deoxynojirimycin (inhibitors of glucosidase I), increased when gp120 was synthesized in the presence of 1-deoxymannojirimycin (mannosidase I) or swainsonine (mannosidase II), and unaffected when gp120 was synthesized in the presence of bromoconduritol (glucosidase II).	1-Deoxynojirimycin	117-135	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	57-62
3264072-3	1988	The electrophoretic mobility of gp120 was decreased when gp120 was synthesized in the presence of castanospermine or 1-deoxynojirimycin (inhibitors of glucosidase I), increased when gp120 was synthesized in the presence of 1-deoxymannojirimycin (mannosidase I) or swainsonine (mannosidase II), and unaffected when gp120 was synthesized in the presence of bromoconduritol (glucosidase II).	1-Deoxynojirimycin	117-135	mannosyl-oligosaccharide glucosidase	Homo sapiens	151-164
3264072-3	1988	The electrophoretic mobility of gp120 was decreased when gp120 was synthesized in the presence of castanospermine or 1-deoxynojirimycin (inhibitors of glucosidase I), increased when gp120 was synthesized in the presence of 1-deoxymannojirimycin (mannosidase I) or swainsonine (mannosidase II), and unaffected when gp120 was synthesized in the presence of bromoconduritol (glucosidase II).	1-Deoxynojirimycin	117-135	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	57-62
3264072-3	1988	The electrophoretic mobility of gp120 was decreased when gp120 was synthesized in the presence of castanospermine or 1-deoxynojirimycin (inhibitors of glucosidase I), increased when gp120 was synthesized in the presence of 1-deoxymannojirimycin (mannosidase I) or swainsonine (mannosidase II), and unaffected when gp120 was synthesized in the presence of bromoconduritol (glucosidase II).	1-Deoxynojirimycin	117-135	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	57-62
3264072-3	1988	The electrophoretic mobility of gp120 was decreased when gp120 was synthesized in the presence of castanospermine or 1-deoxynojirimycin (inhibitors of glucosidase I), increased when gp120 was synthesized in the presence of 1-deoxymannojirimycin (mannosidase I) or swainsonine (mannosidase II), and unaffected when gp120 was synthesized in the presence of bromoconduritol (glucosidase II).	1-Deoxynojirimycin	223-244	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	32-37
3264072-3	1988	The electrophoretic mobility of gp120 was decreased when gp120 was synthesized in the presence of castanospermine or 1-deoxynojirimycin (inhibitors of glucosidase I), increased when gp120 was synthesized in the presence of 1-deoxymannojirimycin (mannosidase I) or swainsonine (mannosidase II), and unaffected when gp120 was synthesized in the presence of bromoconduritol (glucosidase II).	1-Deoxynojirimycin	223-244	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	57-62
3264072-3	1988	The electrophoretic mobility of gp120 was decreased when gp120 was synthesized in the presence of castanospermine or 1-deoxynojirimycin (inhibitors of glucosidase I), increased when gp120 was synthesized in the presence of 1-deoxymannojirimycin (mannosidase I) or swainsonine (mannosidase II), and unaffected when gp120 was synthesized in the presence of bromoconduritol (glucosidase II).	1-Deoxynojirimycin	223-244	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	57-62
3264072-3	1988	The electrophoretic mobility of gp120 was decreased when gp120 was synthesized in the presence of castanospermine or 1-deoxynojirimycin (inhibitors of glucosidase I), increased when gp120 was synthesized in the presence of 1-deoxymannojirimycin (mannosidase I) or swainsonine (mannosidase II), and unaffected when gp120 was synthesized in the presence of bromoconduritol (glucosidase II).	1-Deoxynojirimycin	223-244	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	57-62
2453512-2	1988	In pulse-chase experiments we compared the kinetics of early carbohydrate processing and subsequent secretion of thyroid-stimulating hormone (TSH) and free alpha subunit under control conditions and after treatment with 1-deoxynojirimycin, an inhibitor of glucosidases I and II.	1-Deoxynojirimycin	220-238	mannosyl-oligosaccharide glucosidase	Homo sapiens	256-277
3346233-6	1988	The endomannosidase was not inhibited by a number of agents which are known to interfere with N-linked oligosaccharide processing by exoglycosidases, including 1-deoxynojirimycin, castanospermine, bromoconduritol, 1-deoxymannojirimycin, swainsonine, and EDTA.	1-Deoxynojirimycin	160-178	mannosidase endo-alpha	Homo sapiens	4-19
3346233-6	1988	The endomannosidase was not inhibited by a number of agents which are known to interfere with N-linked oligosaccharide processing by exoglycosidases, including 1-deoxynojirimycin, castanospermine, bromoconduritol, 1-deoxymannojirimycin, swainsonine, and EDTA.	1-Deoxynojirimycin	214-235	mannosidase endo-alpha	Homo sapiens	4-19
2964235-1	1988	Administration in vivo of the alpha-glucosidase inhibitors 1-deoxynojirimycin and its derivatives BAY m 1099 (miglitol) and BAY o 1248 resulted in a dose- and time-dependent decrease in the rate of hepatic glycogenolysis induced by glucagon.	1-Deoxynojirimycin	59-77	sucrase-isomaltase	Homo sapiens	30-47
3027103-6	1987	Deoxynojirimycin, a drug that blocks removal of glucose residues from alpha 1-antitrypsin in the RER and blocks its intracellular maturation, also blocks its appearance in this intermediate compartment.	1-Deoxynojirimycin	0-16	serpin family A member 1	Homo sapiens	70-89
2957325-4	1987	The IgE produced by mouse hybridoma cells in the presence of deoxynojirimycin (dNM), a glucosidase I inhibitor, keeps intact both its antigen and Fc epsilon R-binding capacities.	1-Deoxynojirimycin	61-77	mannosyl-oligosaccharide glucosidase	Mus musculus	87-100
2957325-4	1987	The IgE produced by mouse hybridoma cells in the presence of deoxynojirimycin (dNM), a glucosidase I inhibitor, keeps intact both its antigen and Fc epsilon R-binding capacities.	1-Deoxynojirimycin	79-82	mannosyl-oligosaccharide glucosidase	Mus musculus	87-100
2420791-6	1986	Like the membrane-bound ER alpha-mannosidase, the soluble alpha-mannosidase can hydrolyze alpha-linked mannose from both p-nitrophenyl alpha-mannoside (Km = 0.14 mM) and high mannose oligosaccharides, is not inhibited by the mannose analogues swainsonine and 1-deoxymannojirimycin, is stabilized by MnCl2 or CoCl2, and does not bind to concanavalin A-Sepharose.	1-Deoxynojirimycin	259-280	estrogen receptor 1	Rattus norvegicus	24-32
2939455-9	1986	P815 and R1- cells incubated in the presence of 1-3 mM dNM for 24 hr were considerably less sensitive to lysis by interferon-gamma-activated macrophages than were cells incubated in control medium.	1-Deoxynojirimycin	55-58	interferon gamma	Mus musculus	114-130
2934077-0	1985	Cell type dependent inhibition of transport of cathepsin D in HepG2 cells and fibroblasts exposed to deoxy-manno-nojirimycin and deoxynojirimycin.	1-Deoxynojirimycin	129-145	cathepsin D	Homo sapiens	47-58
2934077-5	1985	In the presence of the glucosidase I inhibitor 1-deoxynojirimycin, the precursor of cathepsin D (larger by about 1 kDa than the secreted form) accumulated transiently in light membranes in HepG2 cells.	1-Deoxynojirimycin	47-65	mannosyl-oligosaccharide glucosidase	Homo sapiens	23-36
2934077-5	1985	In the presence of the glucosidase I inhibitor 1-deoxynojirimycin, the precursor of cathepsin D (larger by about 1 kDa than the secreted form) accumulated transiently in light membranes in HepG2 cells.	1-Deoxynojirimycin	47-65	cathepsin D	Homo sapiens	84-95
3160588-0	1985	Secretion of high-mannose-type alpha 1-proteinase inhibitor and alpha 1-acid glycoprotein by primary cultures of rat hepatocytes in the presence of the mannosidase I inhibitor 1-deoxymannojirimycin.	1-Deoxynojirimycin	176-197	serpin family A member 1	Rattus norvegicus	31-59
3160588-3	1985	When hepatocytes were incubated with the mannosidase I inhibitor 1-deoxymannojirimycin at a concentration of 4 mM, the 49 000-Mr form of alpha 1-proteinase inhibitor and the 39 000-Mr form of alpha 1-acid glycoprotein could be detected in the cells as well as in their media.	1-Deoxynojirimycin	65-86	serpin family A member 1	Rattus norvegicus	137-165
6226656-0	1983	1-deoxynojirimycin impairs oligosaccharide processing of alpha 1-proteinase inhibitor and inhibits its secretion in primary cultures of rat hepatocytes.	1-Deoxynojirimycin	0-18	serpin family A member 1	Rattus norvegicus	57-85
6226656-1	1983	1-Deoxynojirimycin was found to inhibit oligosaccharide processing of rat alpha 1-proteinase inhibitor.	1-Deoxynojirimycin	0-18	serpin family A member 1	Rattus norvegicus	74-102
6226656-3	1983	Hepatocytes treated with 5 mM 1-deoxynojirimycin accumulated alpha 1-proteinase inhibitor as a 51,000 Mr glycoprotein with carbohydrate side chains of the high mannose type, containing glucose as measured by their sensitivity against alpha-glucosidase, the largest species being Glc3Man9GlcNAc.	1-Deoxynojirimycin	30-48	serpin family A member 1	Rattus norvegicus	61-89
6226656-5	1983	In addition, increasing concentrations of 1-deoxynojirimycin inhibited glycosylation resulting in the formation of some alpha 1-proteinase inhibitor with two instead of three oligosaccharide side chains.	1-Deoxynojirimycin	42-60	serpin family A member 1	Rattus norvegicus	120-148
6226656-6	1983	5 mM 1-deoxynojirimycin inhibited the secretion of alpha 1-proteinase inhibitor by about 50%, whereas secretion of albumin was unaffected.	1-Deoxynojirimycin	5-23	serpin family A member 1	Rattus norvegicus	51-79
6226656-7	1983	The oligosaccharides of alpha 1-proteinase inhibitor secreted from 1-deoxynojirimycin-treated cells were characterized by their susceptibility to endoglucosaminidase H, incorporation of [3H]galactose, and [3H]fucose and concanavalin A-Sepharose chromatography.	1-Deoxynojirimycin	67-85	serpin family A member 1	Rattus norvegicus	24-52
6226656-8	1983	It was found that 1-deoxynojirimycin did not completely block oligosaccharide processing, resulting in the formation of alpha 1-proteinase inhibitor molecules carrying one or two complex type oligosaccharides.	1-Deoxynojirimycin	18-36	serpin family A member 1	Rattus norvegicus	120-148
6227481-3	1983	Whereas treatment of IgD- and IgM-producing cells with NM results in the transfer of drastically shortened oligosaccharide side chains, treatment with dNM inhibits trimming, most probably through interaction with glucosidase I and/or II.	1-Deoxynojirimycin	151-154	mannosyl-oligosaccharide glucosidase	Homo sapiens	213-236
6227481-7	1983	The HLA-A, B, C heavy chains synthesized by the Daudi cell line were degraded in an accelerated fashion in dNM-treated cells, but no effects were seen on the HLA-DR antigens in these cells.	1-Deoxynojirimycin	107-110	major histocompatibility complex, class I, A	Homo sapiens	4-12
32564332-9	2021	However, combined treatment with 1-DNJ and ibuprofen prevents loss of mesencephalic dopaminergic neurons, decreases the number of CD68+/ Iba-1+ cells, the microglia/neurons interactions, and the pro-inflammatory cytokines, and improves behavioral changes when compared with MPTP-treated animals.	1-Deoxynojirimycin	33-38	CD68 antigen	Mus musculus	130-134
32564332-9	2021	However, combined treatment with 1-DNJ and ibuprofen prevents loss of mesencephalic dopaminergic neurons, decreases the number of CD68+/ Iba-1+ cells, the microglia/neurons interactions, and the pro-inflammatory cytokines, and improves behavioral changes when compared with MPTP-treated animals.	1-Deoxynojirimycin	33-38	induction of brown adipocytes 1	Mus musculus	137-142
33979163-1	2021	1-Deoxynojirimycin, an alpha-glucosidase inhibitor, possesses various biological activities such as antitumor, antidiabetic, and antiviral effects.	1-Deoxynojirimycin	0-18	sucrase-isomaltase	Homo sapiens	23-40
33979163-4	2021	Among them, compound 10, a conjugate of 1-deoxynojirimycin and kaempferol linked through an undecane chain, exhibited excellent lipophilicity, antiproliferative effects, and alpha-glucosidase inhibitory activity.	1-Deoxynojirimycin	40-58	sucrase-isomaltase	Homo sapiens	174-191
32419574-6	2020	Global inhibition of alpha1,2-mannosidase I activity with deoxymannojirimycin markedly attenuates the glycosylation of CD147 and disrupts its surface distribution at the leading edge, concomitantly reducing the expression of matrix metalloproteinase-9.	1-Deoxynojirimycin	58-77	basigin (Ok blood group)	Homo sapiens	119-124
32419574-6	2020	Global inhibition of alpha1,2-mannosidase I activity with deoxymannojirimycin markedly attenuates the glycosylation of CD147 and disrupts its surface distribution at the leading edge, concomitantly reducing the expression of matrix metalloproteinase-9.	1-Deoxynojirimycin	58-77	matrix metallopeptidase 9	Homo sapiens	225-251
32419574-7	2020	Likewise, treatment with deoxymannojirimycin or siRNA-mediated knockdown of MAN1C1 impairs the ability of the carbohydrate-binding protein galectin-3 to stimulate CD147 clustering in unwounded cells.	1-Deoxynojirimycin	25-44	mannosidase alpha class 1C member 1	Homo sapiens	76-82
32419574-7	2020	Likewise, treatment with deoxymannojirimycin or siRNA-mediated knockdown of MAN1C1 impairs the ability of the carbohydrate-binding protein galectin-3 to stimulate CD147 clustering in unwounded cells.	1-Deoxynojirimycin	25-44	galectin 3	Homo sapiens	139-149
32419574-7	2020	Likewise, treatment with deoxymannojirimycin or siRNA-mediated knockdown of MAN1C1 impairs the ability of the carbohydrate-binding protein galectin-3 to stimulate CD147 clustering in unwounded cells.	1-Deoxynojirimycin	25-44	basigin (Ok blood group)	Homo sapiens	163-168
32806121-1	2020	1-Deoxynojirimycin (1-DNJ) is the major effective component of mulberry leaves, exhibiting inhibitory activity against alpha-glucosidase.	1-Deoxynojirimycin	0-18	sucrase isomaltase (alpha-glucosidase)	Mus musculus	119-136
32806121-1	2020	1-Deoxynojirimycin (1-DNJ) is the major effective component of mulberry leaves, exhibiting inhibitory activity against alpha-glucosidase.	1-Deoxynojirimycin	20-25	sucrase isomaltase (alpha-glucosidase)	Mus musculus	119-136
32806121-5	2020	Enzyme kinetics, molecular docking, fluorescence spectrum, and circular dichroism spectrometry studies indicated that the major mechanism of the synergism is that baicalein was a positive allosteric inhibitor and bound to the noncompetitive site of MGAM, causing an increase of the binding affinity of 1-DNJ to MGAM.	1-Deoxynojirimycin	302-307	maltase-glucoamylase	Mus musculus	249-253
31721020-0	2019	1-Deoxynojirimycin modulates glucose homeostasis by regulating the combination of IR-GlUT4 and ADIPO-GLUT4 pathways in 3T3-L1 adipocytes.	1-Deoxynojirimycin	0-18	insulin receptor	Homo sapiens	82-84
31721020-0	2019	1-Deoxynojirimycin modulates glucose homeostasis by regulating the combination of IR-GlUT4 and ADIPO-GLUT4 pathways in 3T3-L1 adipocytes.	1-Deoxynojirimycin	0-18	solute carrier family 2 member 4	Homo sapiens	85-90
31721020-0	2019	1-Deoxynojirimycin modulates glucose homeostasis by regulating the combination of IR-GlUT4 and ADIPO-GLUT4 pathways in 3T3-L1 adipocytes.	1-Deoxynojirimycin	0-18	adiponectin, C1Q and collagen domain containing	Homo sapiens	95-100
31721020-0	2019	1-Deoxynojirimycin modulates glucose homeostasis by regulating the combination of IR-GlUT4 and ADIPO-GLUT4 pathways in 3T3-L1 adipocytes.	1-Deoxynojirimycin	0-18	solute carrier family 2 member 4	Homo sapiens	101-106
31721020-4	2019	The results demonstrated that the genes/proteins expression of insulin receptor (IR), phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKt/PkB), and adiponectin (ADIPO) increased with the increasing of DNJ concentration from 0.1-10 mumol/L.	1-Deoxynojirimycin	209-212	insulin receptor	Homo sapiens	63-79
31721020-4	2019	The results demonstrated that the genes/proteins expression of insulin receptor (IR), phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKt/PkB), and adiponectin (ADIPO) increased with the increasing of DNJ concentration from 0.1-10 mumol/L.	1-Deoxynojirimycin	209-212	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	86-115
31721020-4	2019	The results demonstrated that the genes/proteins expression of insulin receptor (IR), phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKt/PkB), and adiponectin (ADIPO) increased with the increasing of DNJ concentration from 0.1-10 mumol/L.	1-Deoxynojirimycin	209-212	adiponectin, C1Q and collagen domain containing	Homo sapiens	156-167
31721020-4	2019	The results demonstrated that the genes/proteins expression of insulin receptor (IR), phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKt/PkB), and adiponectin (ADIPO) increased with the increasing of DNJ concentration from 0.1-10 mumol/L.	1-Deoxynojirimycin	209-212	adiponectin, C1Q and collagen domain containing	Homo sapiens	169-174
31721020-5	2019	However the mRNA expression of adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK), glucose transporter 4 (GLUT4) and glucose absorption increased to the maximum at concentration of 5 mumol/L then decreased with further increase of DNJ concentration to 10 mumol/L.	1-Deoxynojirimycin	245-248	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	90-94
31721020-6	2019	Both IR and ADIPO signaling pathways simultaneously affect the glucose homeostasis regulation effect of DNJ, whereas the key response target located in AMPK and its effect on subsequent GLUT4 mRNA expression.	1-Deoxynojirimycin	104-107	insulin receptor	Homo sapiens	5-7
31721020-6	2019	Both IR and ADIPO signaling pathways simultaneously affect the glucose homeostasis regulation effect of DNJ, whereas the key response target located in AMPK and its effect on subsequent GLUT4 mRNA expression.	1-Deoxynojirimycin	104-107	adiponectin, C1Q and collagen domain containing	Homo sapiens	12-17
31164826-3	2019	1-Deoxynojirimycin (DNJ), which is a unique polyhydroxy alkaloid, is the main active component in mulberry (Morus indica L.) leaves and may exhibit protective properties in the prevention of SAP in patients with CHD by affecting the NF-kappaB pathway.	1-Deoxynojirimycin	0-18	nuclear factor kappa B subunit 1	Homo sapiens	233-242
31164826-3	2019	1-Deoxynojirimycin (DNJ), which is a unique polyhydroxy alkaloid, is the main active component in mulberry (Morus indica L.) leaves and may exhibit protective properties in the prevention of SAP in patients with CHD by affecting the NF-kappaB pathway.	1-Deoxynojirimycin	20-23	nuclear factor kappa B subunit 1	Homo sapiens	233-242
31164826-13	2019	DNJ significantly reduced the levels of hs-CRP, IL-6, TNF-a, MDA, SAS, HAMD, AP, and BSS scores and increased SOD level (p < 0.05).	1-Deoxynojirimycin	0-3	C-reactive protein	Homo sapiens	43-46
31164826-13	2019	DNJ significantly reduced the levels of hs-CRP, IL-6, TNF-a, MDA, SAS, HAMD, AP, and BSS scores and increased SOD level (p < 0.05).	1-Deoxynojirimycin	0-3	interleukin 6	Homo sapiens	48-52
31164826-13	2019	DNJ significantly reduced the levels of hs-CRP, IL-6, TNF-a, MDA, SAS, HAMD, AP, and BSS scores and increased SOD level (p < 0.05).	1-Deoxynojirimycin	0-3	tumor necrosis factor	Homo sapiens	54-59
31164826-13	2019	DNJ significantly reduced the levels of hs-CRP, IL-6, TNF-a, MDA, SAS, HAMD, AP, and BSS scores and increased SOD level (p < 0.05).	1-Deoxynojirimycin	0-3	superoxide dismutase 1	Homo sapiens	110-113
31164826-16	2019	DNJ reduced IKK and NF-kappaB levels and increased IkBalpha level (p < 0.05).	1-Deoxynojirimycin	0-3	nuclear factor kappa B subunit 1	Homo sapiens	20-29
31164826-16	2019	DNJ reduced IKK and NF-kappaB levels and increased IkBalpha level (p < 0.05).	1-Deoxynojirimycin	0-3	NFKB inhibitor alpha	Homo sapiens	51-59
30712980-0	2019	Use of a deoxynojirimycin-fluorophore conjugate as a cell-specific imaging probe targeting alpha-glucosidase on cell membranes.	1-Deoxynojirimycin	9-25	sucrase-isomaltase	Homo sapiens	91-108
30712980-2	2019	1-Deoxynojirimycin (DNJ) can be actively captured by cells which express the surface membrane protein alpha-glucosidase.	1-Deoxynojirimycin	0-18	sucrase-isomaltase	Homo sapiens	102-119
30712980-2	2019	1-Deoxynojirimycin (DNJ) can be actively captured by cells which express the surface membrane protein alpha-glucosidase.	1-Deoxynojirimycin	20-23	sucrase-isomaltase	Homo sapiens	102-119
30654939-0	2019	Alpha-glucosidase inhibitor 1-Deoxynojirimycin promotes beige remodeling of 3T3-L1 preadipocytes via activating AMPK.	1-Deoxynojirimycin	28-46	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	112-116
30098884-9	2019	This study elucidated the detailed interaction mechanism of DNJ with glucoamylase, which will be helpful for pharmaceutical companies to design new alpha-glucosidase inhibitor drugs based on polyhydroxylated alkaloids compound like DNJ.	1-Deoxynojirimycin	60-63	sucrase-isomaltase	Homo sapiens	148-165
29957471-6	2018	Therefore, DNJ potentially has the neuroprotective effect by inhibiting BACE1 expression, attenuating Abeta deposition, remitting neuroinflammation, and up-regulating the BDNF/TrkB signal pathway in the brain.	1-Deoxynojirimycin	11-14	beta-site APP cleaving enzyme 1	Mus musculus	72-77
29957471-6	2018	Therefore, DNJ potentially has the neuroprotective effect by inhibiting BACE1 expression, attenuating Abeta deposition, remitting neuroinflammation, and up-regulating the BDNF/TrkB signal pathway in the brain.	1-Deoxynojirimycin	11-14	brain derived neurotrophic factor	Mus musculus	171-175
29957471-6	2018	Therefore, DNJ potentially has the neuroprotective effect by inhibiting BACE1 expression, attenuating Abeta deposition, remitting neuroinflammation, and up-regulating the BDNF/TrkB signal pathway in the brain.	1-Deoxynojirimycin	11-14	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	176-180
29897983-1	2018	1-Deoxynojirimycin (DNJ) is a potent alpha-glucosidase inhibitor and thus beneficial for prevention of diabetes.	1-Deoxynojirimycin	0-18	sucrase-isomaltase	Homo sapiens	37-54
29897983-1	2018	1-Deoxynojirimycin (DNJ) is a potent alpha-glucosidase inhibitor and thus beneficial for prevention of diabetes.	1-Deoxynojirimycin	20-23	sucrase-isomaltase	Homo sapiens	37-54
29915530-7	2018	Finally, we found that the surface mobility of GluN3A-containing NMDARs in hippocampal neurons is increased following incubation with 1-deoxymannojirimycin (DMM, an inhibitor of the formation of the hybrid/complex forms of N-glycans) and decreased in the presence of specific lectins.	1-Deoxynojirimycin	134-155	glutamate ionotropic receptor NMDA type subunit 3A	Homo sapiens	47-53
29725297-15	2018	DNJ consumption decreased the levels of IL-6 and TNF-alpha (P < 0.05).	1-Deoxynojirimycin	0-3	interleukin 6	Mus musculus	40-44
29725297-15	2018	DNJ consumption decreased the levels of IL-6 and TNF-alpha (P < 0.05).	1-Deoxynojirimycin	0-3	tumor necrosis factor	Mus musculus	49-58
29725297-17	2018	DNJ increased the levels of prostaglandin E2, COX-1, COX2, and reduced the levels of and NF-kappaB p65 (P < 0.05).	1-Deoxynojirimycin	0-3	cytochrome c oxidase I, mitochondrial	Mus musculus	46-51
29725297-17	2018	DNJ increased the levels of prostaglandin E2, COX-1, COX2, and reduced the levels of and NF-kappaB p65 (P < 0.05).	1-Deoxynojirimycin	0-3	cytochrome c oxidase II, mitochondrial	Mus musculus	53-57
29725297-18	2018	DNJ showed protection for gastric functions of GU mice by reducing the levels of MOT and SP, and increasing the levels of SS and VIP.	1-Deoxynojirimycin	0-3	vasoactive intestinal polypeptide	Mus musculus	129-132
29718504-6	2018	Correlation analysis showed that the expression levels of Hsp70 and Ser were negatively correlated to DNJ accumulation with weak correlation, while 30K, GST, and TPx genes had positive correlation with DNJ accumulation.	1-Deoxynojirimycin	202-205	thiol peroxiredoxin	Bombyx mori	162-165
29670907-0	2018	Improvement Activity of 1-Deoxynojirimycin in the Growth of Dairy Goat Primary Mammary Epithelial Cell through Upregulating LEF-1 Expression.	1-Deoxynojirimycin	24-42	lymphoid enhancer-binding factor 1	Capra hircus	124-129
29670907-3	2018	The findings showed that, compared to the control, 6 muM DNJ in the DMEM/F12 medium in vitro greatly improved the density of dairy goat breast epithelial cell and significantly increased the LEF-1 mRNA level (P < 0.01) and thus enhanced cell growth.	1-Deoxynojirimycin	57-60	lymphoid enhancer-binding factor 1	Capra hircus	191-196
29670907-4	2018	In addition, DNJ displayed a similar function in alleviating the growth suppression of epithelial cell and the decrease of LEF-1 mRNA level resulting from lentiviral-mediated LEF-1 knockdown.	1-Deoxynojirimycin	13-16	lymphoid enhancer-binding factor 1	Capra hircus	123-128
29670907-4	2018	In addition, DNJ displayed a similar function in alleviating the growth suppression of epithelial cell and the decrease of LEF-1 mRNA level resulting from lentiviral-mediated LEF-1 knockdown.	1-Deoxynojirimycin	13-16	lymphoid enhancer-binding factor 1	Capra hircus	175-180
29670907-7	2018	In conclusion, DNJ could improve breast epithelial cell growth through upregulating LEF-1 expression, which supplied a new means in studying mammary gland growth and development.	1-Deoxynojirimycin	15-18	lymphoid enhancer-binding factor 1	Capra hircus	84-89
29161006-0	2018	ToP-DNJ, a Selective Inhibitor of Endoplasmic Reticulum alpha-Glucosidase II Exhibiting Antiflaviviral Activity.	1-Deoxynojirimycin	4-7	sucrase-isomaltase	Homo sapiens	56-73
29161006-5	2018	ToP-DNJ inhibits ER alpha-glucosidase II at low micromolar concentrations and selectively accumulates in the liver in vivo.	1-Deoxynojirimycin	4-7	sucrase-isomaltase	Homo sapiens	20-37
28341561-1	2017	Duvoglustat HCl (AT2220, 1-deoxynojirimycin) is an investigational pharmacological chaperone for the treatment of acid alpha-glucosidase (GAA) deficiency, which leads to the lysosomal storage disorder Pompe disease, which is characterized by progressive accumulation of lysosomal glycogen primarily in heart and skeletal muscles.	1-Deoxynojirimycin	0-15	alpha glucosidase	Homo sapiens	138-141
28341561-1	2017	Duvoglustat HCl (AT2220, 1-deoxynojirimycin) is an investigational pharmacological chaperone for the treatment of acid alpha-glucosidase (GAA) deficiency, which leads to the lysosomal storage disorder Pompe disease, which is characterized by progressive accumulation of lysosomal glycogen primarily in heart and skeletal muscles.	1-Deoxynojirimycin	17-23	alpha glucosidase	Homo sapiens	138-141
28341561-1	2017	Duvoglustat HCl (AT2220, 1-deoxynojirimycin) is an investigational pharmacological chaperone for the treatment of acid alpha-glucosidase (GAA) deficiency, which leads to the lysosomal storage disorder Pompe disease, which is characterized by progressive accumulation of lysosomal glycogen primarily in heart and skeletal muscles.	1-Deoxynojirimycin	25-43	alpha glucosidase	Homo sapiens	138-141
28341561-6	2017	Following co-administration with duvoglustat HCl, total GAA activity and protein in plasma were further increased 1.2- to 2.8-fold compared to AA alone in all 25 Pompe patients; importantly, muscle GAA activity was increased for all co-administration treatments from day 3 biopsy specimens.	1-Deoxynojirimycin	33-48	alpha glucosidase	Homo sapiens	56-59
28341561-6	2017	Following co-administration with duvoglustat HCl, total GAA activity and protein in plasma were further increased 1.2- to 2.8-fold compared to AA alone in all 25 Pompe patients; importantly, muscle GAA activity was increased for all co-administration treatments from day 3 biopsy specimens.	1-Deoxynojirimycin	33-48	alpha glucosidase	Homo sapiens	198-201
27956035-0	2017	Synthesis and characterization of novel, conjugated, fluorescent DNJ derivatives for alpha-glucosidase recognition.	1-Deoxynojirimycin	65-68	sucrase-isomaltase	Homo sapiens	85-102
27956035-3	2017	The two synthetic conjugates, DNJ-CF31 and DNJ-Me 2, exhibited improved alpha-glucosidase inhibitory effects compared to DNJ and miglitol.	1-Deoxynojirimycin	30-33	sucrase-isomaltase	Homo sapiens	72-89
28798799-5	2017	Results showed that intracerebroventricular (ICV) administration of DNJ reduced hypothalamic ER stress, which activated the leptin-induced Janus-activated kinase 2 (JAK2)/signal transducers and activators of transcription 3 (STAT3) signaling pathway to cause appetite suppression.	1-Deoxynojirimycin	68-71	Janus kinase 2	Mus musculus	139-163
28798799-5	2017	Results showed that intracerebroventricular (ICV) administration of DNJ reduced hypothalamic ER stress, which activated the leptin-induced Janus-activated kinase 2 (JAK2)/signal transducers and activators of transcription 3 (STAT3) signaling pathway to cause appetite suppression.	1-Deoxynojirimycin	68-71	Janus kinase 2	Mus musculus	165-169
28798799-5	2017	Results showed that intracerebroventricular (ICV) administration of DNJ reduced hypothalamic ER stress, which activated the leptin-induced Janus-activated kinase 2 (JAK2)/signal transducers and activators of transcription 3 (STAT3) signaling pathway to cause appetite suppression.	1-Deoxynojirimycin	68-71	signal transducer and activator of transcription 3	Mus musculus	225-230
27604065-0	2016	Bicyclic isoureas derived from 1-deoxynojirimycin are potent inhibitors of beta-glucocerebrosidase.	1-Deoxynojirimycin	31-49	glucosylceramidase beta	Homo sapiens	75-98
27604065-2	2016	Inhibition assays with a panel of glycosidases revealed that these deoxynojirimycin-derived bicyclic isoureas display very potent inhibition against human recombinant beta-glucocerebrosidase with IC50 values in the low nanomolar range.	1-Deoxynojirimycin	67-83	glucosylceramidase beta	Homo sapiens	167-190
26927057-5	2016	Furthermore, DNJ treatment significantly increased hepatic glycogen content, the activities of hexokinase (HK), pyruvate kinase (PK) in liver tissue, and decreased the activities of glucose-6-phosphatase (G6Pase), glycogen phosphorylase (GP), and phosphoenolpyruvate carboxykinase (PEPCK).	1-Deoxynojirimycin	13-16	glucose-6-phosphatase, catalytic	Mus musculus	182-203
26927057-5	2016	Furthermore, DNJ treatment significantly increased hepatic glycogen content, the activities of hexokinase (HK), pyruvate kinase (PK) in liver tissue, and decreased the activities of glucose-6-phosphatase (G6Pase), glycogen phosphorylase (GP), and phosphoenolpyruvate carboxykinase (PEPCK).	1-Deoxynojirimycin	13-16	glucose-6-phosphatase, catalytic	Mus musculus	205-211
26927057-5	2016	Furthermore, DNJ treatment significantly increased hepatic glycogen content, the activities of hexokinase (HK), pyruvate kinase (PK) in liver tissue, and decreased the activities of glucose-6-phosphatase (G6Pase), glycogen phosphorylase (GP), and phosphoenolpyruvate carboxykinase (PEPCK).	1-Deoxynojirimycin	13-16	phosphoenolpyruvate carboxykinase 1, cytosolic	Mus musculus	247-280
26927057-5	2016	Furthermore, DNJ treatment significantly increased hepatic glycogen content, the activities of hexokinase (HK), pyruvate kinase (PK) in liver tissue, and decreased the activities of glucose-6-phosphatase (G6Pase), glycogen phosphorylase (GP), and phosphoenolpyruvate carboxykinase (PEPCK).	1-Deoxynojirimycin	13-16	phosphoenolpyruvate carboxykinase 1, cytosolic	Mus musculus	282-287
26927057-6	2016	Moreover, DNJ increased the phosphorylation of phosphatidylinositol 3 kinase (PI3K) on p85, protein kinase B (PKB) on Ser473, glycogen synthase kinase 3beta (GSK-3beta) on Ser9, and inhibited phosphorylation of glycogen synthase (GS) on Ser645 in liver tissue of db/db mice.	1-Deoxynojirimycin	10-13	extracellular matrix protein 1	Mus musculus	87-90
26927057-6	2016	Moreover, DNJ increased the phosphorylation of phosphatidylinositol 3 kinase (PI3K) on p85, protein kinase B (PKB) on Ser473, glycogen synthase kinase 3beta (GSK-3beta) on Ser9, and inhibited phosphorylation of glycogen synthase (GS) on Ser645 in liver tissue of db/db mice.	1-Deoxynojirimycin	10-13	thymoma viral proto-oncogene 2	Mus musculus	92-108
26927057-6	2016	Moreover, DNJ increased the phosphorylation of phosphatidylinositol 3 kinase (PI3K) on p85, protein kinase B (PKB) on Ser473, glycogen synthase kinase 3beta (GSK-3beta) on Ser9, and inhibited phosphorylation of glycogen synthase (GS) on Ser645 in liver tissue of db/db mice.	1-Deoxynojirimycin	10-13	thymoma viral proto-oncogene 2	Mus musculus	110-113
26927057-6	2016	Moreover, DNJ increased the phosphorylation of phosphatidylinositol 3 kinase (PI3K) on p85, protein kinase B (PKB) on Ser473, glycogen synthase kinase 3beta (GSK-3beta) on Ser9, and inhibited phosphorylation of glycogen synthase (GS) on Ser645 in liver tissue of db/db mice.	1-Deoxynojirimycin	10-13	glycogen synthase kinase 3 beta	Mus musculus	126-156
26927057-6	2016	Moreover, DNJ increased the phosphorylation of phosphatidylinositol 3 kinase (PI3K) on p85, protein kinase B (PKB) on Ser473, glycogen synthase kinase 3beta (GSK-3beta) on Ser9, and inhibited phosphorylation of glycogen synthase (GS) on Ser645 in liver tissue of db/db mice.	1-Deoxynojirimycin	10-13	glycogen synthase kinase 3 beta	Mus musculus	158-167
26927057-7	2016	These results demonstrate that DNJ can increase hepatic insulin sensitivity via strengthening of the insulin-stimulated PKB/GSK-3beta signal pathway and by modulating glucose metabolic enzymes in db/db mice.	1-Deoxynojirimycin	31-34	thymoma viral proto-oncogene 2	Mus musculus	120-123
26927057-7	2016	These results demonstrate that DNJ can increase hepatic insulin sensitivity via strengthening of the insulin-stimulated PKB/GSK-3beta signal pathway and by modulating glucose metabolic enzymes in db/db mice.	1-Deoxynojirimycin	31-34	glycogen synthase kinase 3 beta	Mus musculus	124-133